Metabolic alterations upon SARS

Signal Transduction and Targeted Therapy volume 8, Article number: 237 (2023) Cite this article

3832 Accesses

1 Citations

119 Altmetric

Metrics details

The coronavirus disease 2019 (COVID-19) caused by coronavirus SARS-CoV-2 infection has become a global pandemic due to the high viral transmissibility and pathogenesis, bringing enormous burden to our society. Most patients infected by SARS-CoV-2 are asymptomatic or have mild symptoms. Although only a small proportion of patients progressed to severe COVID-19 with symptoms including acute respiratory distress syndrome (ARDS), disseminated coagulopathy, and cardiovascular disorders, severe COVID-19 is accompanied by high mortality rates with near 7 million deaths. Nowadays, effective therapeutic patterns for severe COVID-19 are still lacking. It has been extensively reported that host metabolism plays essential roles in various physiological processes during virus infection. Many viruses manipulate host metabolism to avoid immunity, facilitate their own replication, or to initiate pathological response. Targeting the interaction between SARS-CoV-2 and host metabolism holds promise for developing therapeutic strategies. In this review, we summarize and discuss recent studies dedicated to uncovering the role of host metabolism during the life cycle of SARS-CoV-2 in aspects of entry, replication, assembly, and pathogenesis with an emphasis on glucose metabolism and lipid metabolism. Microbiota and long COVID-19 are also discussed. Ultimately, we recapitulate metabolism-modulating drugs repurposed for COVID-19 including statins, ASM inhibitors, NSAIDs, Montelukast, omega-3 fatty acids, 2-DG, and metformin.

In the 21st century, coronavirus infections have become major global challenges not only to public health, but also to government managements. Just in the last two decades, we have experienced three pandemic outbreaks caused by ß-coronavirus infections. Coronaviruses are enveloped viruses containing an ~30 kb positive-sense single-stranded RNA [(+) ssRNA] genome.1 Coronaviruses transmit among different species, including humans, livestock, and wild animals. An epidemic caused by SARS-CoV outbroke in China in 2002-2003, culminating in 774 reported casualties. Middle East respiratory syndrome coronavirus (MERS-CoV) accounts for another global outbreak in 2020 with over 800 associated deaths.2 Since December 2019, coronavirus disease 2019 (COVID-19) has caused a global pandemic with symptoms of pneumonia, nausea, fever, and respiratory system impairment.3,4 COVID-19 is caused by a novel pathogen, namely severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Since 2019, COVID-19 has brought unprecedented casualties and socioeconomic burden.4,5

Most COVID-19 cases are asymptomatic or mild. However, some patients have courses characterized by a generalized inflammatory state causing tissue injury in multiple organs and ARDS with a global mortality rate of 3.4%.6 Patients with hypertension, diabetes, and cardiovascular diseases have a higher risk of mortality.7,8 Hitherto, due to a paucity of validated modalities or vaccines, COVID-19 remains a horrendous threat worldwide. Despite enormous scientific efforts that have been dedicated to SARS-CoV-2, the deep layers of SARS-CoV-2 biology and pathogenesis are not yet well understood.

The envelope (E), membrane (M), and spike (S) proteins together comprise the outer shield of SARS-CoV-2; while the core of SARS-COV-2 consists of viral genomic RNA condensed by nucleocapsid (N) protein. The viral genome RNA encodes non-structural proteins (NSPs), structural proteins (E, M, S, and N) and accessory proteins. NSPs are functional in viral RNA replication, protein synthesis, and regulating intracellular signaling pathways.9,10 NSPs also play crucial roles in attenuating host innate immunity to facilitate the escape from host defense and initiate inflammatory response.11 S gives rise to the corona shape of the surface and mediates host receptor recognition and viral entry. SARS-CoV-2 specifically recognizes and attaches human angiotensin-converting enzyme 2 (ACE2) for entry via S protein.12,13 E mediates virus assembly, membrane scission, and budding, playing a pivotal role in virus replication and intercellular transmission.14 M is the most abundant protein in the envelope that directs the assembly process through interaction with the other structural proteins.15 N directly binds with viral RNA, serving as capsulation to protect viral RNA from cytoplasmic immune surveillance and to mediate nucleoprotein complex assembly.16,17,18

The life cycle of coronaviruses generally includes the following stages (as shown in Fig. 1): host cell receptor specific engagement with S protein19; viral uptake by endocytosis or membrane fusion13; uncoating and viral RNA synthesis in replication organelles20,21; progeny virions assembly to mature virions; ultimate release by unknown mechanism.3 Following viral entry by membrane fusion or endocytosis, the release and uncoating of viral genomic RNA, together with NSPs, subject to translation and formation of replication and translation complex (RTC). In the replication stage, viral genomic RNA is coated by double-membrane vesicles (DMVs), which are derived from the endoplasmic reticulum (ER).22 DMVs provide a microenvironment to protect the viral genome and to facilitate viral RNA synthesis.23,24 DMVs have a pore to connect with the cytoplasm for material exchange while shielding viral RNA from intracellular immune surveillance.25 In the assembly stage, newly produced viral RNA and NSPs are subsequently incorporated into virions at the cytoplasmic side of the ER-to-Golgi intermediate compartment (ERGIC).26,27 After being transported to Golgi, coronaviruses are further modified and assembled, giving rise to the morphology of mature virions. Ultimately, virions egress from the host cell by exocytosis. As for the mechanism for viral egress, debates still exist. It was initially postulated that SARS-CoV-2, similar to other enveloped viruses, hijacks the biosynthetic secretory pathway for its exit. However, recent research discovers that coronaviruses including SARS-CoV-2 use lysosome for egress instead of hijacking the biosynthetic secretory pathway.28 Until now, the egress mechanism of coronaviruses has not been determined yet.27,29

The life cycle of SARS-CoV-2. The life cycle of SARS-CoV-2 includes the following stages: receptor recognition via S protein; viral entry through the endocytosis pathway or the membrane fusion pathway; replicative transcription complex formation; viral RNA replication in DMVs; virion assembly in ERGIC; virion maturation in Golgi; egress through an unknown pathway

Lipid metabolism is indispensable in providing energy and material, maintaining homeostasis, regulating immune response, and relaying signals. Many viruses were reported to rewire host cellular lipid metabolism to create replication compartments.30,31,32,33,34 Lipid droplet (LD), a cellular organelle for lipid storage, was reported to be closely associated with cellular antiviral innate immunity.35,36 Lipid accumulation was observed in the lungs of COVID-19 patients and cells infected by SARS-CoV-2, colocalizing with N protein.37,38 Significant lipid pattern alterations were demonstrated by Lipidomic analyses of plasma from COVID-19 patients, and the lipid pattern was shown to correlate with disease severity and progression.39,40

Glucose metabolism is another network that regulates a series of physiological alterations. Aside from providing energy and material for cells, glucose metabolism is also associated with virus infection, immunity, tumorigenesis, homeostasis, and so forth.41,42,43,44,45,46,47 More importantly, it is supported by clinical evidence that diabetes mellitus, which is characterized by an impaired capability to control blood glucose, is a major risk factor predisposing to severe COVID-19.7,48,49 A retrospective study shows that well-controlled blood glucose is associated with markedly lower mortality rates. On the contrary, patients with type 2 diabetes (T2D) or dysregulated blood glucose have poor outcomes.50 Analysis of single-cell RNA-sequencing data in bronchoalveolar lavage fluid immune cells reveals that enhanced glycolysis is the most important metabolic feature of all immune cells in COVID-19 patients.51 The relationship between dysregulated blood glucose profile and COVID-19 is bidirectional. Infection by SARS-CoV-2 could also worsen the condition of type 2 diabetes patients.52,53

Considering the huge socioeconomic damage caused by coronaviruses, it is an urgent need to develop effective therapeutic interventions for the next outbreak. A more profound comprehension of host metabolic alterations and their association with coronaviruses will prompt us to understand more about COVID-19 pathology and promote antiviral drug development. This review aims to generalize and discuss current findings about the role of host metabolism in SARS-CoV-2 infection.

Apart from ACE2, other host receptors including lectins, DC-SIGN, L-SIGN, and AXL, also serve as alternative entry sites of SARS-CoV-2.54,55,56 S protein trimers recognize and bind to cell receptor ACE2 with its S1 domain. Then S protein is cleaved by host transmembrane serine protease TMPRSS2 at the S2’ site.57 The anchored S2 domain is activated to trigger viral and host lipids bilayer fusion, releasing the viral ribonucleoprotein complex into the cell.58,59,60 In addition to the membrane fusion pathway, endocytosis is also hijacked for SARS-CoV-2 entry.61,62 The endocytosis pathway mediates the trafficking of SARS-CoV-2 to the late endosome/lysosome, in which proteases (such as cathepsin L) prime S protein to initiate membrane fusion.63,64

Increasing evidence supports the critical role of lipid rafts in SARS-CoV-2 infection. Lipid rafts are located at cell membranes, they are microdomains enriched in lipid molecules including cholesterol and sphingolipids. Lipid rafts are involved in a variety of physiological processes.65 Lipid rafts are also proposed as important for the entry of other coronaviruses by providing a platform for entry receptors. Lipid rafts are suggested to be a promising therapeutic target.66,67,68 From a mechanistic perspective, lipid rafts provide platforms for membrane receptors involved in viral entry of SARS-CoV-2.69 SARS-CoV-2 entry can be reduced by disturbing lipid rafts. ACE2 colocalizes with well-established raft proteins caveolin-1, flotillin-2, and ganglioside GM1 in Vero E6 cells.70,71 However, either endogenous ACE2 in Vero E6 cells or the transiently expressed ACE2 in CHO cells is not enriched in lipid rafts.72,73 The controversial results might be caused by different experimental methods. How and which receptors are recruited to the lipid rafts requires further investigation.

Changes in cholesterol levels disrupt lipid rafts and the receptors attached.74 SARS-CoV-2 spike-bearing pseudovirus infection is associated with cholesterol-rich lipid rafts.75 Accordingly, Cholesterol-25-hydroxylase, an interferon-stimulated gene (ISG) that triggers cholesterol trafficking from the plasma membrane to ER, inhibits SARS-CoV-2 entry by depriving accessible cholesterol at the plasma membrane. More importantly, the entry inhibition can be restored by replenishing soluble cholesterol to the cells.76 Furthermore, lipid rafts are also proposed to promote viral entry through the endocytosis pathway. SARS-CoV-2 internalization is mediated through a lipid raft-dependent endocytic pathway, but which endocytosis pathway is practically responsible for SARS-CoV-2 entry entails further investigations.75 In some enveloped viruses, infection causes fusogenic viral protein displayed on the cell membrane, which allows adjacent cells to fuse and form multinucleated syncytia.77,78 Syncytia formation is also observed in SARS-CoV-2 infected cells or lungs of deceased patients.79,80 Syncytia formation indicates that SARS-CoV-2 has an ability of cell-to-cell transmission, allowing the virus to avoid contact with antibody.81 Of note, it is evident that cell-to-cell transmission through the formation of channels or syncytia requires intact lipid rafts.82 In addition, S protein-mediated membrane fusion and syncytia formation requires cholesterol involvement.80 Hence, it is reasonable to deduce that lipid rafts are also involved in syncytia formation during SARS-CoV-2 infection.

Intriguingly, S protein can directly interact with cholesterol. A study identified putative cholesterol recognition amino acid consensus motifs in SARS-CoV-2 S protein. Antibodies blocking the cholesterol-binding site of S protein significantly curbed viral entry.83 The interaction between S protein and high-density lipoprotein (HDL) has been interrogated. SR-B1 is an HDL receptor located on the cell membrane that drives the cellular uptake of cholesteryl esters and other lipid components of HDL.84 S protein directly binds with SR-B1-bound HDL and captures lipid materials from HDL. Genetic depletion of SR-B1 curbs SARS-CoV-2 pseudovirus entry.83 Another study also demonstrated that S protein can remove lipid components from HDL. Co-culture of HDL with S protein altered the function of HDL to exchange lipids from model cellular membranes.85

Although cholesterol on cell membrane facilitates viral entry, the role of intracellular cholesterol in SARS-CoV-2 infection is more complicated. Two independent genetical screens by CRISPR libraries identified genes in cholesterol metabolism as essential for SARS-CoV-2 infection, including sterol-regulatory element-binding protein (SREBP-2), SREBP cleavage activating protein (SCAP), low-density lipoprotein receptor (LDLR), and Membrane-Bound Transcription Factor Peptidase, site 1 and 2 (MBTPS1 and MBTPS2). Treatment of amlodipine, a calcium-channel antagonist that increases intracellular cholesterol levels, significantly inhibited SARS-CoV-2 infection.86,87 In addition to facilitating viral entry, it is likely that cholesterol metabolism also affects SARS-CoV-2 infection in other stages of its life cycle. Future studies on the interplay between SARS-CoV-2 and cholesterol metabolism are warranted.

Many viruses including ebola virus (EBOV), human immunodeficiency virus type I (HIV-1), hepatitis C virus (HCV), and simian virus 40 (SV40) are reported to employ sphingolipids for cell membrane attachment.88,89,90,91 The sphingolipid metabolism pathway is also manipulated for SARS-CoV-2 entry (Fig. 2). Sphingolipids and their metabolites together comprise a complex network of signaling in a series of physiological processes, including maintaining cellular structure, relaying signals, and modulating enzymatic activity.92 Elevated sphingolipid levels stimulated by SARS-CoV-2 were observed in cells and mice serum. Analysis of COVID-19 patient serum samples indicated a distinct alteration in sphingolipid profiles. The result shows a progressive increase in dihydrosphingosine, dihydroceramides, ceramides, sphingosine, and a decrease in sphingosine-1-phosphate (S1P).93,94 Acid sphingomyelinase (ASM) catalyzes the hydrolysis of sphingomyelin to ceramide and phosphorylcholine. Increased circulating activity of ASM and derangement of sphingolipids were observed in COVID-19 patients. The increase of ASM activity accurately distinguishes the patient cohorts undergoing intensive care from healthy controls.94 Among the various sphingolipids, the impact of ceramide and sphingosine on SARS-CoV-2 entry is prominent. Ceramide is converted from sphingomyelin by ASM or synthesized de novo from palmitoyl CoA and serine. Several ASM inhibitors including antidepressants (Amitriptyline, Imipramine, Fluoxetine, Sertraline, and Escitalopram) or ASM-knockout potently hindered SARS-CoV-2 entry in vivo. The suppressive effect is exerted partially via an impaired surface ceramide level since the replenishment of exogenous ceramide restored SARS-CoV-2 entry.95 Ceramide-enriched domain formed by released ceramide on the cell surface promoted SARS-CoV-2 entry.96,97 Furthermore, SARS-CoV-2 induced ACE2 clustering in ceramide-enriched domains on the membrane of nasal epithelial cells isolated from healthy donors. Ambroxol, an ASM inhibitor, potently suppressed ACE2 clustering on the cell membrane and reduced viral uptake by the epithelial cells.98 Fluoxetine, amiodarone and imipramine exhibited profound inhibitory activity on SARS-CoV-2 entry. This study indicated that further than removing membrane ceramide, ASM inhibitors can induce endolysosomal cholesterol accumulation and dysregulated acidification, hence blocking SARS-CoV-2 entry via the endosomal pathway.99 It is noteworthy that C16 ceramide presumably plays a central role in promoting SARS-CoV-2 entry since an exogenous supplement of C16 ceramide restored SARS-CoV-2 infection under ASM inhibitors treatment.98 The precise role of ceramide needs to be further defined.

The sphingolipids metabolism pathway. Sphingomyelin on the plasma membrane can be converted to ceramide by sphingomyelinase. Ceramide can also be synthesized de novo from palmitoyl CoA and Serine or synthesized from sphingosine by ceramide synthase. SM Sphingomyelin, Cer ceramide, So Sphingosine, S1P Sphingosine 1-phosphate, HDAL Hexadecenal, PE Phosphorylethanolamine, dhCer dihydroceramide, Sa Sphinganine, KDS 3-ketodihydrosphingosine, P-CoA Palmitoyl-CoA, ASM Acid sphingomyelinase, SMS Sphingomyelin synthase, CDase Ceramidase, CerS Ceramide synthase, SPP S1P phosphatase, SPHK Sphingosine kinase, S1PL S1P lyase, DES dihydroceramide Δ4-saturase, KDSR 3-ketodihydroshpingosine reductase, SPT Serine palmitoyltransferase

Sphingosine derives from ceramide by ceramidase catalyzation or from S1P by S1P phosphatase catalyzation. Sphingosine plays quite a contrary role to ceramide: while ceramide promotes SARS-CoV-2 entry, sphingosine impedes it. Sphingosine binds with membrane ACE2, thereby blocking the interaction between ACE2 and S protein, consequently inhibiting SARS-CoV-2 entry.100 The above findings provide reference for therapeutic interventions since drugs interfering with sphingolipids metabolism pathway like antidepressants are well-tolerated and extensively applied in clinic.101

Glycolipids are essential for SARS-CoV-2 entry, especially sialylated glycolipids. Monosialylated gangliosides have a strong binding affinity with the receptor binding domain (RBD) of S protein. GENZ-123346 is an inhibitor of UDP-glucose ceramide glycosyltransferase (UGCG) that can deplete glycolipids from the cell membranes. GENZ-123346 treatment caused profoundly attenuated SARS-CoV-2 entry in vitro. Consistently, UGCG ablation by CRISPR/Cas9 also curbed SARS-CoV-2 infection.102 Chloroquine binds with sialic acids and gangliosides with a higher affinity than S protein. Treatment of chloroquine or its derivative, hydroxychloroquine, actively reduced SARS-CoV-2 S protein binding with gangliosides and exhibited potent antiviral activity.103,104 Moreover, chloroquine and hydroxychloroquine can be incorporated into endosomes, resulting in an increase of endosomal pH and prevention of viral entry via endocytosis.105 Results from in vitro experiments further confirmed the antiviral effect of chloroquine and hydroxychloroquine against SARS-CoV-2.58 Nevertheless, the clinical use of chloroquine or hydroxychloroquine is still controversial due to insufficient clinical data. Although some clinical studies showed the benefit of chloroquine and hydroxychloroquine, they are not completely reliable because they are non-peer-reviewed, unblinded, or non-randomized.106 Besides, the cardiotoxicity of chloroquine should also be taken into consideration since cardiovascular disorders are also major complications of COVID-19. The European Medicines Agency has refused to approve chloroquine for COVID-19. However, several clinical trials in China proved the efficacy of chloroquine and hydroxychloroquine.107,108,109 The use of chloroquine for the treatment of COVID-19 has been added to the guideline (version 6) in China.

Intriguingly, a recent report identified the bile acid receptor farnesoid X receptor (FXR) as a direct regulator of ACE2 expression. The presence of the FXR responsive element was uncovered in the ACE2 promoter region. Upon activation, FXR directly binds with the ACE2 promoter, confirmed by chromatin immunoprecipitation. Bile acid chenodeoxycholic acid (CDCA) is the major agonist of FXR. Treatment of CDCA markedly upregulated ACE2 expression and enhanced SARS-CoV-2 infection in vitro, in vivo, and in organoids in an FXR-dependent manner. A clinically approved FXR inhibitor, ursodeoxycholic acid (UDCA), significantly downregulated ACE2 expression and exhibited potent antiviral activity in vitro, in vivo, in organoids, and in human organs. In humans, UDCA treatment also decreased ACE2 levels in the nasal epithelium, a primary site for SARS-CoV-2 infection. The retrospective study also demonstrated that patients on UDCA were less likely to develop moderate and severe COVID-19. Altogether, this study demonstrates: (1) FXR directly regulates ACE2 expression; (2) ACE2 levels closely associate with SARS-CoV-2 entry; (3) UDCA could be used as a prophylaxis or a therapy for COVID-19.110

Viral protein modifications are functionally essential in life cycles of coronaviruses. Targeting the post-translation modifications is promising.111,112,113 The lipid modification on S protein is indispensable in SARS-CoV-2 entry. Structural analysis reveals substantial conformational rearrangements of RBD during the infection process: a switch from a closed conformation to an open conformation. In a closed conformation, RBD is buried and less accessible for ACE2 binding; while in an open conformation, RBD exposes the receptor binding motif, enabling ACE2 binding.114,115,116,117 A hydrophobic pocket in S protein was detected, into which linoleic acid fits well. Although the linoleic acid binding pocket is distal from the receptor binding motif, linoleic acid binding results in stabilization of the closed conformation of S protein and compaction of homotrimer architecture, consequently reducing ACE2 binding and membrane fusion.118 Another computational simulation also showed that the presence of linoleic acid in S protein stabilizes the closed conformation and blocks its interaction with ACE2.119 Molecular dynamics simulation revealed that the linoleic acid binding site is coupled to functionally relevant regions of S protein. Removal of a ligand from the linoleic acid binding site disturbed the dynamics of distant functionally important regions of S protein.120

Several studies have reported that protein palmitoylation is crucial in host-virus interaction.121,122,123 Viral protein palmitoylation has a selective advantage among coronaviruses, and the palmitoylation sites are conservative.122 SARS-CoV-2 S protein contains a highly conserved free fatty acid binding pocket with unknown evolutionary selection advantage.124 Quite contrary to linoleic acid, S protein palmitoylation functionally promotes SARS-CoV-2 entry. Palmitoylation site C15 at the N terminus and other sites locating in the cytoplasmic tail of S protein have been identified by two independent studies.125,126 Zinc finger DHHC domain-containing palmitoyltransferase (ZDHHC) inhibitor reduces S protein palmitoylation, consequently decreasing S-mediated syncytia formation and SARS-CoV-2 pseudovirus entry.125 Mutation of palmitoylation sites in the cytoplasmic tail culminated in impeded SARS-CoV-2 pseudovirus entry. The inhibitory effect could be attributed to reduced S protein homotrimer stabilization by depalmitoylation.126 ZDHHC5 and GOLGA7 together form an acyl-transferase complex that mediates protein palmitoylation. The interaction between SARS-CoV-2 S protein and ZDHH5/GOLGA7 complex has been confirmed for S protein palmitoylation.127 Another study suggested that S-acyltransferase ZDHHC20 and 9 mediate the palmitoylation of SARS-CoV-2 S protein.128 Palmitoylation sites have also been observed in the cysteine-rich domain of SARS-CoV S protein, indicating the conservation of S protein palmitoylation.129,130

High glucose levels promote SARS-CoV-2 entry by upregulating ACE2 expression. The major glucose metabolism pathways are shown in Fig. 3. In vitro assay demonstrated that high glucose levels significantly stimulated ACE2 overexpression in A549 cells.131 The correlation between elevated ACE2 expression and diabetes mellitus was also confirmed in mice models.132 A phenome-wide Mendelian randomization study revealed a significant correlation between elevated ACE2 expression and T2D.133 Furthermore, diabetes patients are often treated with ACE inhibitors and hypoglycemic drugs that can upregulate ACE2 expression.134,135,136,137 Notably, elevated ACE2 expression has been directly linked to reinforced viral entry. Increased ACE2 expression in lungs, kidneys, myocardium, and pancreas can promote SARS-CoV-2 binding.138,139 A recent study indicated that glucose treatment induced a dramatic upregulation of ACE2 expression in human kidney organoids, consequently promoting SARS-CoV-2 infection. More importantly, kidney cells from the biopsies of diabetic patients were more susceptible to SARS-CoV-2 infection compared to the kidney cells from healthy controls. From a mechanistic view, hyperglycemia increases the stability of ACE2 mRNA, partially explaining the ACE2 overexpression.140 Therefore, preexisting diabetes, hyperglycemia, and associated medications predispose patients to severe COVID-19 partially via promoting viral entry by upregulating ACE2 expression.

Major pathways of glucose metabolism. Glycolysis, glycogenesis, phosphate pentose pathway, aerobic metabolism, and anaerobic metabolism are included. GLUT glucose transporter, Glc glucose, G6P glucose-6-phosphate, F6P fructose-6-phosphate, FBP fructose-1,6-biphosphate, GA3P glyceraldehyde-3-phosphate, DHAP dihydroxyacetone phosphate, 1,3BPG 1,3-biphosphoglycerate, 3PG 3-phosphoglycerate, 2PG 2-phosphoglycerate, PEP phosphoenolpyruvate, G1P glucose-1-phosphate, UDP-Glc uracil-diphosphate glucose, 6PGL 6-Phosphogluconolactone, 6PG 6-phosphogluconate, Ru5P ribulose-5-phosphate, R5P ribose-5-phosphate, Xu5P xylulose-5-phosphate, S7P Sedoheptulose-7-Phosphate, E4P erythrose-4-phosphate, HK hexokinase, GPI glucose-6-phosphate isomerase, PFK phosphofructokinase, ALD aldolase, GADPH glyceraldehyde-3-phosphate dehydrogenase, PGK phosphoglycerate kinase, PGM Phosphoglycerate mutase, PK pyruvate kinase, GS glycogen synthase, G6PD glucose-6-phosphate dehydrogenase, GNL gluconolactonase, 6PGDH 6-phosphogluconate dehydrogenase, R5PI ribose-5-phosphate isomerase, RPE ribulose-5-phosphate 3-epimerase, TK transketolase, TA transaldolase, LDH lactate dehydrogenase

Viral protein glycosylation plays critical roles in mediating protein folding, stabilization, interaction with host factors, and immune evasion.111,141 Beside lipid modifications, S protein of coronaviruses is also highly glycosylated.142,143,144 Twenty-two N-linked glycosylation sites and several O-linked glycosylation sites have been identified in SARS-CoV-2 S protein and confirmed by mass spectrometry. The glycan types of the O- and N-linked glycosylation have also been investigated.145,146,147,148,149 A high throughput study revealed that mutations at the glycosylation sites could significantly affect the infectivity of S protein pseudo-viruses. The mutations in glycosylation sites at RBD impaired viral infectivity by over 100-fold, suggestive of their functional significance. Furthermore, mutations in glycosylation residues affected the viral sensitivity to antibodies. N165Q mutation increased the sensitivity to neutralizing monoclonal antibodies, while N234Q mutation attenuated it.150 The importance of N-glycans at N165 and N234 in modulating conformational dynamics of S protein was also highlighted by a computational simulation.151 STT3A is a crucial glycosyltransferase that catalyzes N-glycosylation of S protein. N-linked glycosylation inhibitor 1 (NGI-1) inhibits STT3A to reduce S protein N-glycosylation. NGI-1 treatment dramatically decreased the binding ability of recombinant S protein to ACE2 and impaired the infectivity of SARS-CoV-2.152 Blockade of S protein N-glycosylation by genetic approaches or kifunensine (mannosidase-I alkaloid inhibitor) only had a mild impact on S protein-ACE2 binding, but markedly reduced pseudo-virus entry. It is well known that S1-S2 site cleavage is closely associated with viral entry.153,154 Interestingly, the inhibitory effect on reduced N-glycans is mediated through an enhanced S1-S2 site cleavage.155 O-glycans of S protein were also demonstrated to modulate S1-S2 site cleavage. UDP-Gal-NAc:polypeptide N-acetylgalactosaminyltransferases 1 (GALNT1) catalyzes O-glycosylation in residues proximal to the S1-S2 site. O-glycosylation near the cleavage site significantly impeded furin cleavage and syncytia formation. The O-glycosylation is dependent on P681. P681 mutation significantly decreased furin cleavage, O-glycosylation, and syncytia formation.156 In conclusion, both N- and O-glycosylation of S protein affect SARS-CoV-2 entry, partially via disturbing furin cleavage at the S1-S2 site. Targeting enzymes required for S protein glycosylation by inhibitors, such as 2-deoxy-d-glucose (2-DG) or NGI-1, are promising to be used for COVID-19 therapy.157

SARS-CoV-2 reorganizes the ER network and alters the morphology of this organelle to generate viral replication compartments, which contain predominantly DMVs, but also incorporate ER connectors, double membrane spherules, and multi-membrane vesicles. Results from electron tomography showed that DMVs of SARS-CoV-2 are tethered to ER, and several DMVs are attached to the same ER branch, implicating the derivation of DMVs from ER.22 Several independent studies indicated that SARS-CoV-2 can usurp certain stages of the autophagy pathway for DMV formation. Class III phosphatidylinositol 3-kinase (PI3K) mediates autophagosome formation in the autophagy pathway. SARS-CoV-2 uses PI3K to produce phosphatidylinositol 3-phosphate (PI3P) for DMV formation, and PI3K inhibition or genetic depletion profoundly impaired DMV formation and viral replication.158 Several SARS-CoV-2 viral proteins are proposed to manipulate the autophagy pathway. ORF7a reduces lysosome acidity to prevent autophagosome degradation. ORF3a blocks the fusion between lysosomes and autophagosomes, consequently causing the retention of autophagosomes.159,160 The degradation of autophagy-initiating protein Beclin-1 (BECN-1) induces the fusion of autophagosomes with lysosomes, and this process is regulated by Akt/SKP2 pathway.161 In lung samples of COVID-19 patients, phagophore-incorporated autophagy markers LC3B-II and p62 were detected, indicating autophagosome accumulation, which can be attributed to the impact of SARS-CoV-2 on BECN1 levels through AKT1/SKP2 signaling.162 Research on other coronaviruses also underlines the importance of the autophagy pathway in viral DMV formation.163,164 In DMVs, viral RNA and NSPs assemble into RTCs and trigger RNA synthesis.165

Diverse metabolism processes, including fatty acid oxidation, cholesterol catabolism, pentose phosphate pathway, one carbon metabolism, and fatty acid synthesis, are manipulated to fulfill high substrate and energy demand for the replication of (+) ssRNA viruses.30,166,167,168

Phosphatidic acid (PA) is generated by acylglycerolphosphate acyltransferase 1 and 2 (AGPAT1/2) in the ER. It was postulated that PA subverts ER membrane to form replication organelles of SARS-CoV.169 During SARS-CoV-2 infection, AGPAT1/2 were recruited to RTCs and critically contribute to SARS-CoV-2 replication and DMV formation. Pharmacological inhibition of PA synthesis impaired autophagosome-like DMV formation.170 Phosphatidic acid phosphatase 1 (PAP1) converts PA to diacylglycerol, a substrate for phosphatidylethanolamine (PE) and phosphatidylcholine (PC) synthesis.171 Intriguingly, inhibition of PAP1 activity suppressed SARS-CoV-2 replication. PE and PC are essential for (+) ssRNA viral replication via driving replication organelle formation.172,173,174,175,176 Thus, inhibition of PAP1 or AGPATs likely curbs SARS-CoV-2 replication via reducing cellular downstream PE and PC levels.

Fatty acids are also essential for SARS-CoV-2 replication. Pharmacological inhibition of fatty acid synthase impaired SARS-CoV-2 replication, which was restored by exogenously supplied fatty acids.177,178 The exploitation of fatty acids was also seen in Dengue virus infection. NSP3 of Dengue virus recruits fatty acid synthase (FASN) to the replication site and profoundly activates FASN. The author suggests that DENV could co-opt host FASN to establish its replication complexes.179 However, available studies on the exact role of fatty acids in SARS-CoV-2 replication are lacking.

Lipid droplets play a crucial role in viral replication of different viruses including coronaviruses. Disrupting lipid droplets could be a promising therapeutic strategy.35,180,181 Lipid droplets were considered mere lipid storages for a long time, but current findings expand their functions also as central hubs for lipid homeostasis regulation and as effectors in viral infection.168,182,183 Lipid droplets are mainly composed of triacylglycerols, cholesteryl esters, and various enzymes for lipid metabolism, surrounded by a phospholipid monolayer.184,185 Lipid droplet generation is regulated by several enzymes. FASN yields fatty acids, which are further converted to diacylglycerols, and then to triacylglycerols by diacylglycerol o-acyltransferase 1 and 2 (DGAT1/2). Key enzymes responsible for cholesterol synthesis in lipid droplets are acyl-CoA cholesterol acyltransferase 1 and 2 (ACAT1/2).186,187 Since lipid droplets are involved in the replication of many RNA viruses, it is postulated that they probably affect SARS-CoV-2.188 Lipid droplets are found to be located in close proximity to intracellular SARS-CoV-2 particles. In addition, A 922500, a DGAT-1 inhibitor, decreased viral load and ameliorated cytopathy.189 DGAT1/2 and lipid droplet stabilizer adipocyte differentiation-related protein (ADRP) can assist SARS-CoV-2 replication. SARS-CoV-2 N protein is demonstrated to upregulate DGAT1/2 expression to generate lipid droplets. N protein interacts with ADRP on the lipid droplet surface to favor viral replication.190 Peroxisome proliferator-activated receptor-α (PPAR-α) induces lipid droplet degradation by β-oxidation. Palmitoylethanolamide (PEA), a PPAR-α agonist, significantly suppressed SARS-CoV-2 replication by decomposing lipid droplets.191 NSP6 was proposed to mediate the contact of SARS-CoV-2 replication organelle with lipid droplets by recruiting the lipid droplet-tethering complex DFCP-1.192

TMEM41B, an ER-localized protein, has been identified as a mediator for lipid mobilization from lipid droplets.193,194 TMEM41B is a paramount host factor with diverse functions in coronavirus replication.195,196 Two independent genome-wide screens identified TMEM41B as an important host factor for SARS-CoV-2 replication. Inhibition or genetic ablation of TMEM41B attenuated SARS-CoV-2 replication in an early post-entry stage. Although TMEM41B is involved in the autophagy pathway,197,198 the impact of TMEM41B on lipid localization and trafficking from lipid droplets mainly accounts for assisting viral replication since knockout of TMEM41B did not compromise SARS-CoV-2 replication via suppressing the induction of autophagosomes.199,200 Collectively, the above studies suggest that TMEM41B mediates the lipid exchange between SARS-CoV-2 replication organelle and lipid droplets. In a genome-wide CRISPR/Cas-9 knockout screen, TME41B was also identified as a conserved host factor required for replication among coronaviruses.201

It is well-known that SARS-CoV-2 infection also causes a shift of glucose metabolism to aerobic glycolysis, namely the Warburg effect.202,203,204 Most viruses including coronaviruses induce Warburg effect in favor of their replication.205 Glycolysis provides energy and building blocks for nucleotide synthesis, which is conducive to viral RNA replication. Other viruses are reported to hijack glycolysis for RNA and protein synthesis.205,206 Metabolomic analysis showed lower intracellular glucose levels and higher lactate levels at early time points after SARS-CoV-2 infection, suggestive of enhanced glycolysis to meet the massive demand for viral replication.207 Proteomics study revealed an increased protein cluster of carbon metabolism during SARS-CoV-2 infection, and blockade of glycolysis by 2-DG prevents SARS-CoV-2 replication.208 It was also reported that SARS-CoV-2 triggered ROS production to stabilize HIF-1α, culminating in the Warburg effect.209 Moreover, the blockade of HIF-1α by GW6471 effectively inhibited SARS-CoV-2 infection in airway organoids.210

The Warburg effect leads to an increase in the activity of hexokinase (HK), which is the first rate-limiting enzyme of glycolysis. HK catalyzes the generation of glucose-6-phosphate, the primary material for the pentose phosphate pathway (PPP). The PPP generates NADPH and ribose-5-phosphate to provide material and energy for a variety of cellular events.211,212 Glucose-6-phosphate dehydrogenase (G6PD) is an important enzyme in PPP that converts glucose-6-phosphate to 6-phosphogluconolactone. G6PD was found to be upregulated in lungs obtained from deceased COVID-19 patients.213 The PPP was also proposed to be involved in SARS-CoV-2 replication to meet the high demand for ribose-5-phosphate for viral RNA synthesis. SARS-CoV-2 infection upregulated the levels of two constituents in the non-oxidative PPP branch: transketolase and transaldolase 1. Benfooxythiamine, a transketolase inhibitor, significantly curbed SARS-CoV-2 replication. 2-DG interferes with glycolysis to reduce the material for the PPP. The combination of 2-DG and benfooxythiamine synergistically restrained SARS-CoV-2 replication, indicating that PPP inhibition and glycolysis inhibition can independently restrain SARS-CoV-2 replication.214

Folate is required for one-carbon unit transfer, which is essential for purine de novo synthesis. The one-carbon metabolism is shown in Fig. 4. Folate species convey one carbon unit to mediate de novo purine synthesis.215,216 Metabolomic analysis detected the accumulation of intermediates of de novo purine synthesis in SARS-CoV-2-infected cells. Intracellular glucose and folate were found to be depleted during the infection of SARS-CoV-2, indicative of the consumption of them. Methotrexate is a folate analog that disrupts one carbon pathway. Treatment of methotrexate markedly reduced SARS-CoV-2 RNA levels, viral protein expression, and virion production, highlighting the importance of one carbon pathway and de novo purine synthesis in SARS-CoV-2 replication.207 Notably, methotrexate is FDA-approved for inflammatory disorders with a good safety profile. Thus, methotrexate is prospective to be applied to SARS-CoV-2 therapy.

One carbon metabolism. One carbon metabolism mainly contains the folate cycle and the methionine cycle. SAM provides methyl for methylation, then it is recycled by the methionine cycle. Folate drives the folate cycle to mediate transfer of one carbon unit and purine de novo synthesis. THFA tetrahydrofolate, 5-MTHF 5-methyltetrahydrofolate, 10-CHO-THF 10-formyltetrahydrofolate, 5,10-CH2-THF 5,10-methylene tetrahydrofolate, Hcy homocysteine, Met methionine, SAH S-adenosylhomocystein, SAM S-adenosylmethionine, MeT methyltransferase, MTR methionine synthase

One carbon metabolism also affects SARS-CoV-2 replication by boosting S-adenosylmethionine (SAM)-dependent methylation. RNA capping plays a key role in viral replication by evading the immune system, maintaining RNA stability, and initiating translation.217 RNA capping machinery is employed by different species of coronaviruses.218,219,220 SARS-CoV-2 also employs RNA capping. In SARS-CoV-2, the RNA cap is composed of a 7-methylguanosine linked to the 5’ nucleotide of the viral RNA through a triphosphate bridge. The cap is methylated at the N7 site of the guanosine, using SAM as a methyl donor, forming m7GpppN-RNA, mediated by NSP14.221 Then, SAM-dependent 2’-O-methyltransferase adds a methyl group to the ribose 2’-O site of the nucleotide to consequently form the cap (m7GpppNm-RNA), mediated by NSP16.222 Folate metabolism fuels SAM production by maintaining the methionine cycle. The methionine cycle is essential for the generation of SAM through the adenylation of methionine.223 SAM cycle inhibitors or genetic ablation of main enzymes in the SAM cycle were shown to dramatically restrict SARS-CoV-2 replication. More importantly, 3-deazaneplanocin A, an FDA-approved drug that can disrupt SAM production, exhibited excellent antiviral potency.224

SARS-CoV-2 assembly occurs in the ERGIC.27,29 Structural proteins are essential for this process. After replication, newly synthesized RNA exits DMVs through molecular phores.25 A protein inside DMVs, probably an RNA-dependent RNA polymerase (RdRp), is hypothesized to guide the viral RNA through these pores. Viral RNA is subsequently condensed by N protein.225 The N-RNA complex is organized to form G-shape ribonucleoproteins (RNPs). During assembly, N protein induces N-RNA complex phase separation via its central disordered domain.225 SARS-CoV M protein interacts with N protein via their highly hydrophilic and charged carboxy groups, overlaying the N-RNA complex into the particle.226,227 Despite functional studies on SARS-CoV-2 M protein are still blank, considering the high homology between SARS-CoV M protein and SARS-CoV-2 M protein, SARS-CoV-2 M protein possibly incorporates N-RNA complex with the same strategy.228 The interaction between E and M in coronaviruses is well-established. Co-expression of the M and E proteins is sufficient for virion maturation and release.229,230,231 E and M interacts with each other via the C-terminal domain of both proteins at the cytoplasmic side of ERGIC.105,232 E protein is able to oligomerize to form a pentamer and serves as a cation channel to increase pH in ERGIC.233 S is considered less involved in the assembly process since viral assembly without S is not affected.229 S protein clusters through M-S interaction when the N-RNA complex is incorporated into a newly formed particle.29 M is indispensable for S incorporation into virions.227 Both M and E induce maturation and S location in ERGIC.234

The process of viral release is one of the least understood stages in the life cycle of SARS-CoV-2. Previously, it was a mainstream theory that coronaviruses primarily egress through the biosynthetic secretory pathway. However, a recent finding from transmission electron microscopy proposes that coronavirus including SARS-CoV-2 more likely egresses in small secretory vesicles.235 Another study proposes a model in which coronaviruses egress by lysosomes instead of the biosynthetic secretory pathway. The lysosomes were deacidified with proteolytic enzymes inactivated in cells infected by SARS-CoV-2.28 The mechanism of SARS-CoV-2 release remains a question of debate. Hence, there are few available studies connecting viral exit and host lipids.

Cellular lipids play crucial roles in multiple processes of SARS-CoV-2 assembly. M binds with lipid headgroups through their C-terminus domain. When M homodimer is in an open conformation, cholesterol and inositol lipids accumulate in the vicinity of the homodimer, while phosphatidylserines accumulate near a monomer of the homodimer. The author suggests that the lipid-protein interplay explains membrane curvature formation induced by M protein.236

E protein is a functional membrane morphogen. When synthesized alone, E reconfigures intracellular membranous organelles into elongated swirls.237 Palmitoylation of coronavirus E protein is functionally important in viral assembly.238,239,240 Palmitoylation of E protein occurs in a conserved cysteine-rich region near the transmembrane domain, which is primarily catalyzed by the DHHC-rich domain palmitoyl acyltransferase that resides in ER and Golgi. These integral membrane proteins transfer palmitate residing in the DHHC motif to the cysteine residues in the acceptor proteins.241,242 Mouse hepatitis coronavirus (MHC) E protein has three conserved cysteine residues in their cysteine-rich regions. Replacement of cysteine residues in MHC E protein by alanines or glycines culminated in failed virus-like particle secretion and disturbed virion assembly when expressed along with N, M, and S protein.240 Triple cysteine/alanine mutations in the cysteine-rich region led to significantly reduced MHC virus yields in the infected cells. Furthermore, MHC E protein lacking all three cysteines exhibited an increased rate of degradation, indicating a compromised stability.243 In SARS-CoV, E also undergoes intracellular post-translational modifications. Palmitoylation of SARS-CoV E protein is functionally essential for maintaining stability.244 Since the sequence of SARS-CoV-2 E protein is 95 % identical to the counterpart of SARS-CoV, SARS-CoV-2 E protein palmitoylation probably has a similar function. Molecular dynamic simulations on SARS-CoV-2 E protein indicate that palmitoylated E protein is more stable. In the absence of palmitoylation, the pentameric structure of E proteins lost dynamic equilibrium, and the pore radius of E protein drastically decreased and even collapsed.245,246 Since both S and E proteins require palmitoylation to maintain their functional architecture, inhibitors targeting palmitoyl acyltransferase are of interest.

Common symptoms of COVID-19 are mild, including fever, diarrhea, and cough, accounting for ~70% of patients.247 However, some patients progressed to more severe syndromes. Manifestations of severe COVID-19 patients are predominantly ARDS, thrombotic complications that mimic disseminated intravascular coagulopathy, and multi-organ failure. The pathology of COVID-19 is complicated and not fully elucidated, involving disruption of immune balance, systemic inflammation, complement hyperactivation, etc.3,248

An abnormal elevation of pro-inflammatory cytokines (IL-2R, IL-6, IL-8, TNF-α, et al.) and chemokines (CCL2, CCL8, CXCL9, et al.), together with an altered lymphocyte subset profile was observed in COVID-19 patients, reflecting the onset of autoimmune-related disorders.249,250 Intracellular innate immunity is also disrupted by SARS-CoV-2 for immune evasion.251 Interferon I-III (IFN I-III), nuclear factor-κB (NF-κB), toll-like receptor 4 (TLR4), retinoic-acid inducible gene I (RIG-1)-like receptor (RLR)/mitochondria anti-virus signaling protein (MAVS) pathways are all reported to be disturbed by SARS-CoV-2 with concomitant dysfunctional antiviral immunity and abnormal cytokine secretion.252,253,254,255,256,257,258,259 In extreme cases, the immune system over-reacts to the virus and triggers a fatal cytokine storm which is characterized by uncontrolled excessive pro-inflammatory cytokine release and hyperactivated immune cells. In a cytokine storm, immune cells erroneously attack normal host cells, causing collateral multi-tissue damages and multi-organ failure, bringing poor prognosis and even mortality.260,261,262 A cytokine storm was suggested as a major cause of lung damage in COVID-19.263,264,265 Coagulopathy in COVID-19 patients was evidenced by significantly elevated levels of D-dimer (a biomarker of coagulopathy) and thrombocytopenia in hospitalized patients.7 A large proportion of severe COVID-19 patients obtained a hypercoagulable state that predisposed patients to thrombosis. The Post-mortem of lung tissues revealed thrombogenesis in small arteries and capillaries of the pulmonary vasculature.266,267,268 The etiology of thrombosis in COVID-19 is under investigation. Coagulopathy, complement activation, pro-inflammatory cytokine release, platelet hyperactivation, and endothelial dysfunction are emerging as potential major contributors to thrombosis.269 Several compounds that ameliorate inflammation response have been demonstrated to alleviate symptoms of COVID-19. Dexamethasone is a corticosteroid widely used to treat a range of infections by resolving inflammation and suppressing abnormally elicited immune responses.270 In patients who need ventilation, dexamethasone decreased the mortality rate by approximately one-third.271 Baricitinib is a reversible JAK1/2 inhibitor that regulates inflammation and immune responses. In hospitalized COVID-19 patients, treatment with Barcitinib effectively decreased the mortality rate.272 Given that host lipids have immunomodulatory properties, they are supposed to be involved in SARS-CoV-2-elicited disorders. This section focuses on the role of host metabolism in the pathogenesis of COVID-19.

Eicosanoids are inflammation mediators originated from the processing of arachidonic acid (AA). AA is generated by the cleavage of membrane phospholipids by phospholipase A2 (PLA2). AA can be processed by cyclooxygenases (COX) or lipoxygenases (LPX) to produce prostaglandins (PGs), thromboxanes (TXs), or leukotrienes (LTs), which all play regulatory roles in immune homeostasis (the AA metabolism pathway is shown in Fig. 5). Analysis of bronchoalveolar lavage fluid of COVID-19 patients showed elevated PGE2, TXB2, 12-HHTrE, and leukotriene B4 (LTB4) levels compared to healthy controls, and the eicosanoid levels were positively correlated with the levels of cytokines (IL-1α, IL-6, TNF-α, IL-12p70, IL-22, and IFN-α2) and chemokines (CCL2, CCL11, CXCL9, and CXCL10).273

Arachidonic acid metabolism. The arachidonic metabolism pathway includes three branches: 1. CYP enzymes convert arachidonic acids to ETTs or HETEs. 2. 5-lipoxygenase catalyzes arachidonic acids to lipoxins and leukotrienes 3. The COX-1/COX-2 pathway that produces prostaglandins. AA arachidonic acids, PGG2 prostaglandin G2, PGH2 prostaglandin H2, TXA2 thromboxane A2, PGE2 prostaglandin E2, PGI2 prostaglandin I2, PGD2 prostaglandin D2, PGF2α prostaglandin F2α, 5-HPETE 5-hydroperoxyeicosatetraenoic acid, LXB4 lipoxin B4, LXA4 lipoxin A4, LTA4 leukotriene A4, LTB4 leukotriene B4, LTC4 leukotriene C4, LTD4 leukotriene D4, LTE4 leukotriene E4, ETTs epoxyeicosatrienoic acids, HETEs hydroxyeicosatetraenoic acids, DiHPAs dihydroxydocosapentaenoic acids, DHEQs dihydroxyeicosatetraenoic acids, DHETs dihydroxyeicosatrienoic acids, PLA2 Phospholipase A2, COX-2 cycloxygenase-2, COX-1 cycloxygenase-1, 5-LOX 5-Lipoxygenase, 12-LOX 12-Lipoxygenase, LTC4S LTC4 synthase, LTA4H LTA4 hydrolase, TXAS Thromboxane A synthase, PEG2I PEG2 isomerase, PGIS prostaglandin I synthase, PGD2 I PGD2 isomerase, PGF2αR PGF2α reductase, CYP cytochrome P450, sEH soluble epoxide hydrolase

In hospitalized patients, plasma PLA2 levels positively correlated with disease severity and acute multisystem inflammatory syndrome.274 Lipidomic analysis on plasma samples of COVID-19 patients also identified PLA2 as an indicator of severity. Deceased patients had higher levels of PLA2 compared with survivors.275 The correlation could be attributed to downstream products of AA metabolism.

COX-1 and COX-2 catalyze AA to prostaglandin H2, which is further converted to diverse bioactive prostaglandins (PGs). PGE2, the most abundant PG, is an important mediator of a series of physiological processes, especially initiation and regulation of inflammation.276 SARS-CoV-2 can stimulate COX-2 overexpression in diverse human cell lines.277 Risk factors for severe COVID-19 courses include obesity, older ages, and a sedentary lifestyle, and all these risk factors positively correlated with patient serum PGE2 levels. Clinical research revealed that in COVID-19 patients, high serum PGE2 levels are associated with poor prognosis. The increased COX-2 levels were observed in living human precision-cut lung slices, implying the causal relationship between ARDS and PGE2. Lymphopenia characterized by a drastic reduction of lymphocytes is generally accompanied by a poor prognosis of COVID-19 patients.278 PGE2 can suppress PAX5, a regulator of B cell proliferation and survival, thereby partially contributing to the lymphopenia.279 A comparatively low level of PGE2 enhances immunity while a high level of it compromises the immune system by killing lymphocytes.280 Another prostaglandin PGD2, synthesized by COX, also contributes to lymphopenia. PGD2 production can be upregulated by SARS-CoV infection, which subsequently disturbs lymphocyte priming and maturation via DP1 and DP2 signaling.281 The physiological function of PGE2 and PGD2 are double-edged and dose dependent. Both PGE2 and PGD2 can induce a lipid mediator class switching of eicosanoid production by neutrophils from the 5-lipoxygenase pathway to lipoxins, resolvins, and protectins.282 Hence, COX inhibitors should be used with caution.

Another COX downstream product thromboxane A2 (TXA2) also accounts for COVID-19 pathogenesis. TXA2 is synthesized from PGH2 predominantly by platelet COX. TXA2 induces platelet aggregation and thrombi generation. In COVID-19 patients, P-selectin, a marker of platelet activation expressed on the surface of platelet, is overexpressed. Plasma thrombopoietin levels are also upregulated, reflecting hyperactive platelet. Platelet extracted from COVID-19 patients aggregated faster and exhibited increased spreading on both fibrinogen and collagen. Otherwise, both circulating platelet-neutrophil and platelet-monocyte aggregates increased in COVID-19 patients, reflecting platelet hyperactivation and thrombogenesis. The platelet hyperactivation can be partially explained by MAPK activation and increased TXA2 production.283,284

Leukotrienes are produced from AA by 5-lipoxygenase. Leukotriene A4 (LTA4) is generated directly from AA, then converted to LTB4 in neutrophils and monocytes. Alternatively, LTA4 can also be converted to leukotriene C4 (LTC4) by LTC4 synthase. Outside the cell membrane, LTC4 is catalyzed to leukotriene D4 (LTD4) and leukotriene E4 (LTE4). LTC4, LTD4 and LTE4 are termed cysteinyl-leukotrienes.285 Leukotrienes act as chemotactic factors for the recruitment of lymphocytes, monocytes, and macrophages to peripheral tissues and are intimately related to the pro-inflammatory function of monocytes and macrophages.286,287,288 Considering the high neutrophil infiltration and high neutrophil/lymphocyte ratios in tissues of COVID-19 patients, leukotrienes are proposed to be involved.289 Moreover, single-cell analysis of bronchoalveolar immune cells and PBMCs from COVID-19 patients shows elevated 5-lipoxygenase expression.290,291 Leukotrienes also trigger cytokine (TNF-α, IL-1, IL-6, CCL2, etc.) release in the microenvironment to amplify inflammatory responses.292,293 Cysteinyl-leukotrienes activate platelet by binding with cysteinyl-leukotrienes receptors on platelet, culminating in thromboxane release and consequent coagulopathy as well as lung immunopathology in COVID-19.248,294,295 Besides, leukotrienes provoke atherosclerosis, plasma leakage, and ARDS, which are canonical manifestations of severe COVID-19.288,296 Lipidomic analysis of bronchoalveolar lavage fluid extracted from COVID-19 patients who require mechanical ventilation shows significantly elevated leukotrienes levels, predominantly LTB4, LTE4, and eoxin E4, supporting the deleterious role of leukotrienes.297 However, there are scarce studies on the precise role of leukotrienes in COVID-19 due to the difficulty in measuring leukotriene levels since they undergo rapid physiological metabolism. Of note, inhibition of COX could lead to an imbalance of AA metabolism and provoke leukotriene production, which partially explains why NSAIDs are of little benefit to severe COVID-19 patients.

Despite the benefit of inhibiting AA metabolism, inhibition of PLA2 may also downregulate pro-resolving factors which ameliorate inflammation. AA is a substrate for another enzymatic pathway, the cytochrome P450 (CYP) system. CYP system consists of two metabolic branches: ω-hydroxylases which convert AA to hydroxyeicosatetraenoic, and epoxygenases which convert AA to regioisomeric epoxyeicosatrienoic acids.298 Epoxyeicosatrienoic acids accelerate the termination of inflammation responses by mediating an array of anti-inflammatory and pro-resolving processes.298,299 Epoxyeicosatrienoic acids mitigate the release of pro-inflammation cytokines and chemokines, including IL-6, IL-1β, and MCP-1.300 In vivo, epoxyeicosatrienoic acids are constantly hydrated to dihydroxyeicosatrienoic acids by soluble epoxide hydrolase (sEH). Hence, inhibiting sEH can effectively upregulate epoxyeicosatrienoic acids levels. TPPU, an inhibitor of sEH, is able to block neutrophil infiltration to the lung, decrease pro-inflammatory cytokine levels in serum and bronchoalveolar lavage fluid, and ameliorate alveolar capillary leakage in an LPS-induced acute lung injury mouse model.301 Thus, although PLA2 inhibitors theoretically ameliorate COVID-19 by reducing downstream pro-inflammatory mediators, they possibly also hinder pro-resolution and anti-inflammation processes, consequently exacerbating the condition.

Besides AA metabolism, ASM/ceramide system also mediates inflammation and thrombogenesis during SARS-CoV-2 infection. In patients with community-acquired pneumonia, serum phospholipid levels greatly plunged, while ceramide levels increased and ASM activity was consistently enhanced.302 Sphingolipids are intimately associated with inflammation. In a mouse model, genetic ablation or pharmacological inhibiting ASM activity profoundly reduced pro-inflammatory cytokine production.303 Another study evaluated ASM serum activity in a mixed intensive care unit (ICU) population. Higher serum ASM levels in non-survivors and lower ASM levels in survivors were observed, and correlated with the mortality rates in ICU patients with systemic inflammation.275 In endothelial cells stimulated with serum from sepsis patients, plasma ASM activity and levels were profoundly enhanced, leading to endothelial stress response and cytotoxicity. However, pharmacological or genetic inhibition of ASM improved the sepsis-induced endothelial stress.304 More importantly, ASM also works as a pathogenic mediator of ARDS.305 Severe COVID-19 is usually accompanied by a hypercoagulable state, and tissue factors are the primary cellular initiator of coagulation.306,307 In common conditions, tissue factors remain cryptic, and sphingomyelin can maintain tissue factors in the encrypted state. However, hydrolysis of sphingomyelin by ASM activates tissue factors, culminating in coagulation. SARS-CoV-2 spike protein pseudovirus markedly enhanced the procoagulant ability of tissue factors, while inhibition or silencing ASM attenuated SARS-CoV-2 pseudovirus-induced tissue factor activation.308 Given that ASM activation plays dual roles in both viral entry and pathogenesis, ASM inhibitions are supposed to alleviate COVID-19 severity.309

Besides viral entry, the dysregulated cholesterol metabolism also causes deterioration of COVID-19 through modulating inflammatory response. It is a prevalent phenomenon that patients with lower pre-infection HDL levels underwent severe COVID-19 with higher mortality rates. Cholesterol, HDL, and LDL levels are lower in patients who underwent severe COVID-19 compared to patients with non-severe COVID-19.310,311,312,313 Cholesterol is closely associated with immunometabolism. Cholesterol accumulation in macrophages and other immune cells promotes inflammation by amplification of Toll-like receptor (TLR) signaling, inflammasome activation, and production of monocytes and neutrophils.314,315 Cholesterol trafficking to ER can activate NLRP3 inflammasome, a key mediator of infection-induced inflammation, consequently promoting inflammation and pro-inflammatory cytokine secretion. Treatment with statins abrogated NLRP3 inflammasome assembly and IL-1β secretion.316,317 Cellular cholesterol levels are mainly monitored in ER membrane by liver X receptor (LXR), Sterol regulatory element binding protein-2 (SREBP2), and erythroid 2 related factor1 (NRF1).318 When the cholesterol content in ER decreases, SREBP-2 migrates from ER to Golgi, then it is activated and translocated into the nucleus to trigger downstream transcription.319 SREBP-2 serves as a hub to connect cholesterol levels to immune response. Mechanistically, upon detecting the decreased intracellular cholesterol level, SREBP-2 associates with NLRP3 to form a tertiary structure that translocates to Golgi to facilitate inflammasome assembly.320 Furthermore, SREBP-2 interplays with NF-κB to mediate inflammation.321,322 Evidence supports that SARS-CoV-2 manipulates SREBP-2 to stimulate cytokine storm. SREBP-2 was highly elevated in the PBMCs of COVID-19 patients, and the mRNA levels of SREBP-2 positively correlated with disease severity. In addition, SREBP-2 C-term, the cleaved form of SREBP-2, significantly increased in the serum of severe and deceased COVID-19 patients. Treating with Fatostatin A, an SREBP-2 processing inhibitor, effectively suppressed pro-inflammatory cytokine production in the PBMCs of COVID-19 patients. Fatostatin A can also protect human umbilical vein endothelial cells (HUVEC) from LPS stimuli, indicative of the vascular protective function.323 It is interesting to interrogate whether circulating SREBP-2 C-term directly contributes to COVID-19 progression or not. Of note, SARS-CoV-2 infection mitigates intracellular cholesterol levels. SARS-CoV-2 likely reduces the intracellular cholesterol to activate SREBP-2.

HDL is mainly responsible for the cellular efflux of cholesterol. By promoting cholesterol efflux, HDL reduces cholesterol accumulation in immune cells.324 HDL is proposed to have anti-inflammatory, antioxidant, antiviral, anti-coagulant, and vascular protective properties, working as pathogen scavengers that potentially involves in the removal of infectious material. In addition, HDL prevents infection of various DNA and RNA viruses by neutralization.325,326,327 HDL levels negatively correlated with COVID-19 severity and decreased with the deterioration of patients’ conditions, indicating that high HDL levels prevent severe COVID-19. In spite of the close association between HDL and COVID-19 severity, detailed studies on the interplay between COVID-19 and HDL are scarce. The relationship between cholesterol metabolism and immunometabolism is intertwined, and the cellular cholesterol level alteration during COVID-19 is dynamic and not fully interpreted. Better comprehension will optimize the use of statins for the treatment of COVID-19.

The association between COVID-19 and dysregulated glucose metabolism is bidirectional. Pre-existing T2D or hyperglycemia are identified as risk factors for severe COVID-19 with high mortality rates.328,329 On one hand, glucose metabolism facilitates SARS-CoV-2 entry and replication. On the other hand, SARS-CoV-2 infection worsens the situation of T2D or even mediates the onset of new type 2 diabetes.204 The interplay between dysregulated glucose profiles and poor outcomes in COVID-19 patients is complicated and not fully known. However, SARS-CoV-2 can impair islet function by directly infecting pancreatic cells. Human pancreatic cells express SARS-CoV-2 entry receptors including ACE2, TMPSSR2, and neuropilin-1 (NRP-1). SARS-CoV-2 infection can restrict insulin secretion and induce β cell apoptosis in vitro.330 SARS-CoV-2 also infects the induced pluripotent stem cell (iPSC)-derived pancreatic cultures containing endocrine and exocrine cells and provokes inflammatory responses. Of note, the autopsy of patients who died of COVID-19 confirms the SARS-CoV-2 infectivity of the pancreas.331 Approximately 17% of severe COVID-19 patients display an increased level of amylase and lipase (two biomarkers of pancreas injury), indicative of the caused pancreatic injury.332 It is also proposed that the usage of steroids during the treatment might contribute to the onset of hyperglycemia and diabetes.333 Considering the risk of hyperglycemia during infection, hospital protocols should include the management of hyperglycemia in COVID-19 patients.

Preexisting hyperglycemia or diabetes mellitus also worsens the situation of COVID-19 patients by affecting immune responses. Diabetes mellitus is characterized as a chronic inflammatory status. It is well-known that diabetes mellitus affects both innate and adaptive immunity.334 A previous clinical study shows that subjects with impaired glucose tolerance have higher levels of plasma inflammatory cytokines including IL-6, TNF-α, and IL-18 via an oxidative mechanism.335 Higher glucose levels stimulate inflammatory cytokine secretion of periphery blood mononuclear cells (PBMCs) and impede innate immunity by inhibiting type I IFN production.336 Another report indicates that COVID-19 patients with diabetes mellitus have higher levels of plasma inflammatory biomarkers including C-reactive protein, serum ferritin, IL-6, and a higher erythrocyte sedimentation rate.337 A retrospective multicenter study demonstrates that COVID-19 patients with diabetes have a higher likelihood of developing lymphopenia.50 Monocytes infected by SARS-CoV-2 produce more inflammatory cytokines, which are further augmented by higher glucose levels. Blockade of glycolysis by 2-DG significantly decreased the viral load and inflammatory cytokine secretion. From a mechanistic view, the infection induces ROS production to stabilize HIF-1α, consequently promoting glycolysis. This metabolic alteration of monocytes directly inhibits T cell responses, partially explaining the lymphopenia.209 Thus, hyperglycemia and diabetes mellitus likely trigger or exacerbate inflammation to culminate in poor prognosis of COVID-19 patients. The impaired innate immunity caused by high glucose levels is also conducive to SARS-CoV-2 infection.

Lactate is a byproduct of glucose metabolism and the end-product of anaerobic glycolysis. Since SARS-CoV-2 infection enhances glycolysis, the level of lactate concomitantly increases. Recently, lactate is revealed to have diverse functions in regulating T cell proliferation, immune cell metabolism, macrophage polarization, and cytokine production.338,339,340,341 COVID-19 patients with higher lactate levels tend to worse outcomes.342 The lactate generation is catalyzed by lactate dehydrogenase (LDH). LDH regulates the interconversion of pyruvate and lactate, which is a crucial step in the anaerobic metabolism of glucose. The high LDH levels correlate with disease progression in COVID-19 patients.328,343,344 Besides being used as an indicator of severe COVID-19, lactate potentially contributes to disease progression. Lactate can rewire CD4+ T cell metabolism, leading to a deterioration of chronic inflammation diseases.340 Results from a previous study show that high lactate levels are associated with more prothrombotic fibrin properties and neutrophil extracellular trap (NET) formation, which are crucial mediators of coagulopathy in COVID-19.345,346 Moreover, lactate is an activator of HIF-1α. Lactate preconditioning can shift cellular glucose metabolism to glycolysis. By stabilizing HIF-1α, lactate promotes glycolysis in a positive feedback manner, thus facilitating SARS-CoV-2 infection.347,348 Intriguingly, lactate is also a suppressor of RLR-mediated innate immunity. Pattern recognition receptor RLRs are RNA sensors for triggering innate immune responses against viral infection. Lactate inhibits RLR signaling and type I IFN production by preventing MAVS mitochondrial localization/aggregation, and RIG-1-MAVS association. Reduction of lactate levels by pharmacological inhibition of lactate dehydrogenases A (LDHA) profoundly increased the resistance of mice against viral infection by upregulating type I IFN production.349 This finding explains the potential benefits of shifting glucose metabolism towards glycolysis for evading innate immune responses. However, the exact role of lactate in the pathogenesis of COVID-19 is intricate and not exhaustively studied.

Human intestines are inhabited by over 2000 species of microbes (microbiota). It has been shown gut microbiota have many biological functions including shaping and modulating immune responses. Dysbiosis of gut microbiota could lead to aberrant immune responses or autoimmune diseases.350,351 More importantly, the composition of gut microbiota is closely related to inflammatory cytokine secretion, which is surprisingly reminiscent of the inflammatory comorbidities and cytokine storm caused by COVID-19.352 Analysis of stool samples from COVID-19 patients revealed that the composition of microbiota in COVID-19 patients underwent significant alterations. The abundance of probiotics was depleted meanwhile the abundance of opportunistic pathogens increased. The baseline abundance of Coprobacillus, Clostridium ramosum, and Clostridium hathewayi increases with disease severity. On the other hand, the abundance of Faecalibacterium prausnitzii inversely correlates with COVID-19 severity.353 Another study showed that COVID-19 patients had markedly less bacterial diversity, and the impaired bacterial diversity was associated with increased severity. This study also identified a decreased abundance of Bifidobacterium, Faecalibacterium, and Roseburium, and an increased abundance of Bacteroides in COVID-19 patients comparing to exposed controls.354 The levels of plasma cytokines and inflammatory markers in COVID-19 patients were closely associated with microbiota composition, linking gut microbiota to COVID-19-induced inflammatory disorders and tissue damage. Several species known to play immunoregulatory roles in human gastrointestinal tracts including Bifidobacterium adolescentis, Eubacterium rectale, and Faecalibacterium prausnitzii are depleted in COVID-19 patients. However, this study demonstrated no differences in bacterial diversity between COVID-19 patients and healthy controls.355 Since the study of human microbiota is still in its cradle, how SARS-CoV-2 affects microbiota is not fully elucidated yet. COVID-19 is accompanied by a set of sequelae even after complete disease resolution, namely long COVID-19 or post-COVID-19 syndromes, including fatigue, memory loss, anxiety, anosmia, and depression.356,357 Gut microbiota is closely related to long COVID-19. Altered microbiota composition and decreased bacterial diversity were detected in post-COVID-19 patients, even eight months after acute disease resolution.358 Patients with long COVID-19 had distinct microbiota composition compared to completely recovered patients. While there was no significant difference in microbiota between patients with or without antibiotic treatment, indicating that the difference was not due to antibiotic use. Intriguingly, different post-COVID-19 syndromes were associated with different microbiota patterns. For example, respiratory symptoms were positively correlated with opportunistic pathogens, while neuropsychiatric symptoms and fatigue were accompanied by changes in nosocomial pathogens. More importantly, composition at admission can predict the onset of post-COVID-19 syndromes, underlining the important role of microbiota.359 Of note, microbiota composition could be modified by dietary supplements. Some researchers suggested replenishment of probiotics by a plant-based rich fiber diet or other nutritional modulations that could be beneficial to COVID-19 patients.360,361,362,363 Otherwise, the influence on microbiota should be taken into consideration when using antibiotics for the treatment of COVID-19 patients. Compared with gut microbiota, lung microbiota was less investigated. However, recent findings support that lung microbiota also played an important role in COVID-19 pathology. Lung microbiota is involved in respiratory infections diseases and pneumonia.364,365 But due to the difficulty in measuring the composition of the microbial community in patients, the role of lung microbiota in COVID-19 is poorly understood.

As mentioned above, long COVID-19 is manifested by a series of post-infection syndromes even a long period after the nucleic acid test shows a negative result. Over 200 symptoms have been identified in long COVID-19, some of them were severe and debilitating. For example, a meta-analysis showed that 22% of patients had cognitive impairment 12 weeks post-infection.366 Cognitive impairment is a canonical symptom of long COVID-19. The magnitude of cognitive impairment in long COVID-19 is equal to 10 years of cognitive aging, and likely increases over time.367 It is even more concerning that hospitalized and non-hospitalized patients have similar rates of developing cognitive impairment.368 Otherwise, many patients have other sequelae including multi-organ dysfunction, gastrointestinal disorders, respiratory disturbances, and cardiovascular disorders.369,370,371 The etiology of long COVID-19 is multifactorial. Major contributors to long COVID-19 are proposed to be abnormally altered immune system, circular system dysfunction, multi-organ damage, and neuroinflammation.372,373 Considering the deleterious effect of long COVID-19, exploring the mechanism and prophylaxis is of importance. Many long COVID-19 patients shared similar symptoms with Myalgic encephalomyelitis/chronic fatigue syndromes (ME/CFS), a multisystem neuroimmune disorder that generally happens after infection. ME/CFS was manifested by chronic fatigue, cognitive impairment, and post-exertional malaise.374,375 Therefore, therapeutic strategy for ME/CFS presumably also alleviated COVID-19. Dietary supplementation of coenzyme Q can reduce fatigue and oxidative stress in ME/CFS.376 The effect of coenzyme Q on long COVID-19 is being clinically tested. It is also noted that mast cell activation was prevalent in long COVID-19 patients, implying the causal link between mast cell activation and long COVID-19.377,378 The proposed mechanism is that aberrant mast cell activation triggers mediators including histamine, cytokines, leukotrienes, and prostaglandins, bringing damage to multiple tissues. Antihistamine treatment is the protocol for mast cell activation syndrome. Pilot studies have demonstrated that antihistamines can relieve long COVID-19-associated symptoms.379,380 Some components of traditional herbs including quercetin and luteolin are also proposed for the prevention or treatment of long COVID-19, although there is no clinical evidence till now.381 It is noteworthy that physical exercises exacerbate the condition of COVID-19 patients instead of improving it. According to a survey, regular physical exercises worsened the condition of 74.84% long COVID-19 patients, only 0.84% patients reported improvement by physical exercises.382 Hence, long COVID-19 patients should take caution when practicing. Although long COVID-19 brings enormous health burdens to patients, there are few clinical studies available now.

Patients with severe COVID-19 undergoing mechanical ventilation have a poor prognosis, and even some recovered patients have severe sequelae, such as lung fibrosis, chronic vasculitis, hypertension, and embolism.383,384 Considering the urgency, repurposing FDA-proved drugs with a verified safety profile is of interest. This section focuses on the repurposing of FDA-proved drugs that intervene in host lipid metabolism for the treatment of COVID-19 and their clinical research. The clinical trials are summarized in Table 1.

Statins have been applied in clinic for decades with a proven efficacy and safety for the treatment of hyperlipidemia and as prophylaxis of atherosclerosis disease.385 HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase (HMGCR) is a rate-limiting enzyme for cholesterol biosynthesis. Statins are strong competitive inhibitors of HMGCR and are generally used as lipid-lowering drugs. Statins effectively reduce plasma cholesterol levels by inhibiting cholesterol biosynthesis and lowering low-density lipoprotein (LDL) levels.386 Since cellular cholesterol plays a critical role in SARS-CoV-2 viral entry, statins have bright prospects for treating COVID-19.

Clinical reports of COVID-19 patients revealed a correlation between cholesterol metabolism and prognosis. Statistical analysis shows that a higher serum high-density lipoprotein cholesterol (HDLc) level predicts a lower mortality rate before infection by SARS-CoV-2.310 Total cholesterol, LDL, and HDL levels decreased in COVID-19 patients compared to the levels prior to infection. Total cholesterol and LDL recovered to baseline in discharged patients but progressively dropped in non-survival patients.387 Given that statins manage cholesterol profiles, they could improve the conditions of COVID-19 patients.

Aside from regulating cholesterol levels, statins have diverse effects independent of HMGCR inhibition, including stablizing endothelial dysfunction, regulating atherosclerosis, anti-fibrosis, anti-thrombosis, anti-oxidantion, anti-apoptosis, and anti-inflammation.388 The impact of statins on ARDS is controversial, two clinical studies show no improvement in ARDS under statins treatment versus placebo.389,390 While another study indicates a potential benefit to ARDS patients associated with statin use.391 Meta-analysis indicates that statin practically prolongs ventilator-free days of patients with ARDS, although it does not improve mortality and severe sepsis.392

A retrospective study of COVID-19 patients shows that the 28-day all-cause mortality rate was 5.2% and 9.4% in the matched statin and non-statin groups, respectively.393 Another retrospective study confirms that COVID-19 patients admitted to ICU who used atorvastatin had a slower progression to death and a lower mortality rate.394 Meta-analysis of 19 studies involving over 395,000 patients indicates that prior statin use is associated with a lower risk of mortality and a reduced risk of severe COVID-19.395 However, another study obtained a different result: prior treatment of statins improves neither severity outcome nor mortality rates. The contradictory results may be caused by the risk of exacerbating compensatory immune signals through the effect of statins on TLR and NF-κB.396 In addition, results from clinical studies show that statin treatment upregulates ACE2 expression, thereby potentially facilitating SARS-CoV-2 attachment and entry. Hence, whether statins practically improve COVID-19 severity and prognosis or not remains a matter of debate.397

Most antidepressants belong to functional inhibitors of acid sphingomyelinase (FIASMAs) and are widely applied as psychotropic medications. Antidepressants, such as fluoxetine, fluvoxamine, paroxetine, and amitriptyline, have been widely used for decades with proven safety.398 As discussed above, evidence supports the central role of ASM/ceramide system during SARS-CoV-2 infection. FIASMAs, which practically reduce ceramide levels, are promising to serve as a therapeutic modality for COVID-19. They regulate pro-inflammatory cytokine secretion and thereby display anti-inflammatory properties. They also interact with ER chaperone the Sigma-1 receptor and ER stress sensor inositol-requiring enzyme 1α to regulate cytokine secretion and immune response.399 Besides blocking SARS-CoV-2 viral entry, FIASMAs can also ameliorate COVID-19 via their immune modulatory property.400,401

The potency of FIASMAs has been validated. A multicenter study on hospitalized severe COVID-19 patients shows a reduced risk of intubation or death under FIASMA treatment (37.5% FIASMA group vs 41.4% non-FIASMA group). The correlation between taking FIASMAs and reduced likelihood of intubation or death is not specific to one particular class of FIASMAs.402 Another cohort study on severe COVID-19 patients reveals that chronic prescription of FIASMA is associated with a lower risk of mortality. In this study, amlodipine exhibited the most prominent efficacy among FIASMAs. Patients treated with amlodipine before the infection had a lower rate of mortality (12.7%) than patients not treated with amlodipine before the infection (34.9%).403 In a randomized double-blinded clinical trial, fluvoxamine reduced the likelihood of clinical deterioration compared to the placebo group.404 In another randomized clinical trial, the proportion of patients observed in a COVID-19 emergency setting or transferred to a tertiary hospital due to COVID-19 was lower in the fluvoxamine group compared with the placebo group.405 Collectively, these clinical results support FIASMAs as an effective modality for COVID-19.

Non-steroidal anti-inflammatory drugs (NSAIDs), the COX-1 and COX-2 inhibitors, are prospective as a therapy for COVID-19. NSAIDs are well-tolerated anti-inflammatory drugs that are widely used for managing acute or chronic inflammatory diseases. A retrospective study indicates that the use of NSAIDs is associated with a reduced risk of hospitalization of COVID-19 patients with chronic inflammatory diseases.406 Another study obtained a similar conclusion: COVID-19 patients prescribed ibuprofen or naproxen had a lower risk of hospitalization.407

However, the application of NSAIDs on COVID-19 remains controversial. Some propose that NSAIDs usage upregulates ACE2 expression, thus promoting SARS-CoV-2 entry while other studies demonstrate that NSAIDs have no impact on ACE2 expression and will not exacerbate infection.408,409,410,411 There are also concerns that NSAIDs could exacerbate hypercoagulation and the incidence of thrombosis due to decreased thrombomodulin caused by NSAID treatment.412,413 Furthermore, NSAIDs may predispose patients to gastrointestinal and cardiovascular complications which are also canonical symptoms of COVID-19.414

Although the World Health Organization has declared that there is no evidence of an increased risk of disease deterioration, considering the potential adverse effects, NSAIDs should be used with caution on COVID-19 patients.

Montelukast is a cysteinyl leukotriene receptor antagonist that blocks the binding of cysteinyl leukotrienes. Montelukast was initially used for the treatment of chronic asthma with excellent safety. Montelukast can effectively suppress inflammation by inhibiting NF-κB activation and the downstream pro-inflammatory cytokines (IL-6, TNF-α, MCP-1, et al.) secretion in cultured human mononuclear cells and macrophages upon stimulation.415,416 In addition, montelukast is also capable of inhibiting platelet activation under the stimulation of serum from COVID-19 patients by downregulating the surface expression of tissue factors and P-selectin. As a consequence, the formation of monocyte- and granulocyte-platelet aggregates are profoundly inhibited.417

Montelukast also affects the viral proteins of SARS-CoV-2. A computational simulation predicts that montelukast may bind S protein to disturb the RBD domain.418 Montelukast sodium hydrate binds with the C-terminus domain of SARS-CoV-2 NSP1 protein to restore host protein synthesis, which is suppressed by NSP1.419,420

Hospitalized patients treated with montelukast experienced significantly fewer events of clinical deterioration compared with patients not receiving montelukast (10% vs 32%).421 Montelukast treatment alleviated the severity of COVID-19, prevented lung respiratory failure, and reduced mortality.422 Montelukast is currently under phase III clinical trial (NCT04389411) for the treatment of severe COVID-19.

Pro-resolving mediators, e.g., lipoxins, resolvins, protectins and maresins, stimulate key cellular events in resolution, namely cessation of neutrophil infiltration and enhanced macrophage uptake of debris, hence actively protecting tissues from hyperinflammation and expediting recovery from inflammatory damage.423 Treatment with such pro-resolving mediators accelerates the clearance of bacteria and impedes neutrophil accumulation in the lung, thereby promoting the resolution of bacteria-induced lung injury.275 These pro-resolving mediators are synthesized from two Omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic (DHA). Both serve as precursors in the biochemical pathways leading to Specialized pro-resolving mediators.424 Therefore, exogenous supplementation of omega-3 fatty acids is recommended to treat COVID-19 via the pro-resolving process.425

Omega-3 index (O3I) reflects blood levels of EPA and DHA. It was revealed a lower O3I as a risk factor for severe COVID-19A study after comparison of O3I levels in hospitalized severe COVID-19 patients with ambulatory patients with mild infection.426 A randomized double-blinded study was conducted to investigate the therapeutic effect of omega-3 fatty acid supplementation on severe COVID-19 patients. The result is encouraging, it showed that omega-3 fatty acid supplementation improved the levels of several parameters of respiratory and renal function in critically ill patients and increased the survival rate.427 Omega-3 fatty acids are well-known as anti-inflammatory and pro-resolving factors and confirmed to improve the conditions of COVID-19 patients.425,428

2-DG is a synthetic analog of glucose that interferes with glycolysis. 2-DG has been used in diverse areas for decades, including antivirus, anticancer, and antiepileptic.429,430,431 As mentioned above, SARS-CoV-2 induces the Warburg effect, and its infection highly depends on glycolysis. The transition of glucose metabolism to glycolysis favors SARS-CoV-2 entry, replication, and pathogenesis. Moreover, 2-DG also inhibits the PPP pathway and glycosylation of S protein. Hence, 2-DG is presumably promising to ameliorate the severity of COVID-19.202,203

2-DG treatment significantly reduced the viral load of cells infected by SARS-CoV-2 and ameliorated the CPE and cell death. Surprisingly, the progeny SRAS-CoV-2 generated from 2-DG-treated cells exhibited weakened infectivity.432 However, 2-DG has potential toxicity. 2-DG can cause glucocytopenia in the nervous system, and irregularities in the cardiovascular, respiratory, and immunological systems.433,434 In a randomized phase II clinical study, 2-DG was administered as an adjunct to stand of care (SOC). Patients treated with 90 mg/kg/day 2-DG had better outcomes. The clinical recovery and vital signs normalization were faster in the 90 mg/kg/day 2-DG group. However, in this study, 30.3% of patients reported adverse events.435 In 2021, 2-DG was approved by the Drug Controller General of India as an adjunct therapy along with the SOC in hospitalized patients with mild to severe COVID-19. The clinical data indicates that patients treated with 2-DG + SOC underwent a quicker symptomatic relief and normalization of vital sign factors compared with SOC alone. The clinical data is accessible from the trials’ registrations on the Clinical Trial Registry of India. Notably, continuous administrations of high 2-DG doses over a long time might cause toxicity to the individuals. Considering the adverse effects, 2-DG should be used with caution.

Metformin has been used as a first-line anti-diabetic drug for decades. Recent research reveals that metformin also possesses anti-cancer, anti-aging, anti-inflammatory, and other properties.436,437,438,439 Due to the prominent bioactivity of metformin, it is also proposed for the treatment of COVID-19.

Several observational studies have confirmed the beneficial effect of metformin on COVID-19. As mentioned above, diabetic mellitus, dysregulated glucose metabolism, and hyperglycemia are risk factors for severe COVID-19. A large-scale retrospective study including over 2,800,000 COVID-19 patients with diabetes has been conducted to evaluate the influence of different glucose-lowering drugs. Patients prescribed metformin have markedly less COVID-19-related mortality rates compared with those prescribed insulin. However, several confounding factors have not been adjusted in this study.440 Another two small-scale retrospective studies indicate that, after adjusting confounding factors, metformin use is still associated with lower mortality rates in COVID-19 patients with diabetes.441,442 Intriguingly, the beneficial effect of metformin is shown to be gender-dependent. Metformin treatment profoundly alleviates the severity in female COVID-19 patients, while the effect on male patients is minimal. Researchers propose that this difference is probably due to the stronger suppressive effect of metformin on TNF-α production in women than in men, suggesting that metformin alleviates COVID-19 primarily via regulating inflammatory cytokines.443 Several clinical trials are currently being conducted. Those clinical studies demonstrate that metformin treatment prevented disease progression and reduced mortality rates. However, further studies are needed through randomized, double-blinded clinical trials.

From a mechanistic perspective, metformin presumably ameliorates COVID-19 via multifaceted effects. Metformin can prevent endothelial dysfunction, reduce cytokine release, improve glucose metabolism, and promote resolution of lung damage after acute inflammation. All these effects are considered to be responsible for alleviating COVID-19 severity.444,445,446,447,448 Considering the distinct therapeutic effect between males and females, the anti-inflammatory effect seems to play a major role. However, the practical mechanism needs to be experimentally investigated.

In this review, we summarize the advances and provide comprehensive knowledge of metabolic alterations induced by SARS-CoV-2 and how they influence SARS-CoV-2 infection in aspects of entry, replication, assembly, and pathogenesis. We also include studies of drugs repurposed for COVID-19.

Like other coronaviruses, SARS-CoV-2 entry entails the intact lipid rafts on cell membranes.449,450,451 The paramount importance of lipid rafts during SARS-CoV-2 entry was underpinned and summarized by several researchers.75,452 The role of cellular cholesterol metabolism is controversial and not fully interpreted. Some researchers suggest that SARS-CoV-2 downregulates cellular cholesterol levels, and increased cholesterol levels impede SARS-CoV-2 infection. However, others suggest that cholesterol depletion restrains SARS-CoV-2 infection. The inconsistent results could be due to different time points, positions, treatments, methods, and so forth. The exact role of cholesterol entails further studies. Cholesterol might influence SARS-CoV-2 infection in post-entry stages including replication, virion maturation, and egress, although there is currently no available study. It would be also interesting to interrogate how increased cellular cholesterol restrains SARS-CoV-2 infection. Ceramides assist SARS-CoV-2 entry by forming ceramide-rich microdomains where ACE2 clusters. Contrarily, sphingosine, the downstream metabolite of ceramides, impedes SARS-CoV-2 entry by blocking the interaction between S protein and ACE2. S1P is a product downstream of sphingosine. The anti-inflammatory and anti-thrombotic properties of S1P are well-established. S1P is postulated to ameliorate COVID-19 by protecting endothelial barrier, although there is no available study.453,454 Considering the intimate relationship between COVID-19 and sphingomyelin metabolism, other components in sphingomyelin are probably involved in different stages of SARS-CoV-2 infection. Interrogating the ER branch of sphingomyelin metabolism would be of interest since SARS-CoV-2 replication organelles are also derived from ER. Lipid modifications of S protein have been intensively investigated. The modification by linoleic acid locks the S protein in a closed conformation and prevents viral entry, while the palmitoylation of the S protein stabilizes the S protein homotrimer, thereby promoting viral entry. S protein of MHV is also demonstrated to be palmitoylated, and mutation at the palmitoylation sites impeded MHV penetration into cells and reduced specific infectivity, indicating the conservation of S protein palmitoylation among coronaviruses.455 Hyperglycemia or diabetes mellitus facilitates SARS-CoV-2 entry by upregulating ACE2, partially accounting for the worse situation of COVID-19 patients with preexisting diabetes. The glycosylation of S protein also significantly contributes to viral entry.

Host lipids also contribute to SARS-CoV-2 replication. The glycerophospholipid metabolism pathway facilitates SARS-CoV-2 replication by facilitating DMV formation. However, which step of the glycerophospholipid metabolism is responsible remains unknown. PE and PC are downstream metabolites of PA, and both were reported to hijack RNA virus replication,173,175,176,456 but currently there is no available data on the role of PE and PC in SARS-CoV-2 replication. Deciphering the roles of PC and PE during SARS-CoV-2 infection is of interest. The employment of host LDs by SARS-CoV-2 to meet the energy and material demand for replication was evidenced by current findings. The involvement of LDs was well-elucidated in other RNA viruses including hepatitis C virus, rotavirus, Zika virus, and dengue virus.181,457,458,459,460 The PPP generates nucleotides for viral replication, partially explaining the benefit of the Warburg effect induced by SARS-CoV-2. The onset of the Warburg effect is also seen in other virus infection.205,461,462 One carbon metabolism provides material for SARS-CoV-2 RNA capping, which is important for viral replication. The cap formation is conveyed by NSPs, primarily NSP9, and NSP12.463,464 Capping at the 5’ of viral RNA can prevent RNA degradation by innate immune responses and facilitates viral protein translation.222 Of note, phosphatidylinositol phosphate biosynthesis is revealed to be essential for SARS-CoV-2 infection. SARS-CoV-2 infection is highly dependent on phosphatidylinositol phosphate biosynthesis.86,87 In addition to contributing to replication compartment formation, phosphatidylinositol phosphate biosynthesis likely promotes SARS-CoV-2 in different stages of its life cycle. Further studies would be of interest.

The next section depicted how host lipids assist SARS-CoV-2 assembly. M protein uses several lipid components to induce membrane curvature. E protein palmitoylation is supported by computational simulations, and the adduct of palmitate is able to maintain E protein functional architecture. It was previously hypothesized that β-coronaviruses employ the biosynthetic pathway for egress. However, recent findings suggested β-coronaviruses employ deacidified lysosomes for virion release.28,465,466 Due to a paucity of comprehension of coronavirus egress mechanism, related studies are insufficient. Considering that the lysosomes are intimately connected to the lipid metabolism of LDs and ER, research on the association between host lipids and viral exit is warranted.467,468

Severe COVID-19 is manifested by ARDS, hyperinflammatory status, thrombotic complications, and multi-organ failures. This paper reviewed the impact of host lipids on COVID-19 pathogenesis. Eicosanoids of the AA pathway including prostaglandins, thromboxanes, and leukotrienes as well as the ASM/ceramide system are included as they affect thrombotic and inflammatory status during SARS-CoV-2 infection. The importance of cholesterol in COVID-19 is interpreted in this section. The bidirectional relationship between COVID-19 and dysregulated glucose metabolism was discussed. The role of lactate is also incorporated. Recent studies indicate that many COVID-19 patients underwent microbiota dysbiosis, and microbiota associates with COVID-19 severity via the gut-lung axis.469,470,471 The alteration of microbiota composition and its important role in COVID-19 is exhaustively discussed. However, available studies on the mechanism underlying the onset of long COVID-19 are few. Treatments and prophylaxis for long COVID-19 needs to be further validated by clinical studies.

Ultimately, several lipid-modulating and glucose-modulating drugs repurposed for COVID-19 are overviewed. Statins, ASM inhibitors, NSAIDs, Montelukast, Omega-3 fatty acids, 2-DG, and metformin are summarized. Further long-term follow-up studies are needed to characterize the benefit of these drugs for treating COVID-19 patients. Coronaviruses have given rise to three pandemics with huge damage to our society in the last two decades. However, therapies with proven efficacy are still lacking till now. Understanding the interaction between coronaviruses and host metabolism will prompt antiviral drug development and better disease management that would apply not only to SARS-CoV-2 infection, but also potentially to other types of coronavirus infections.

He, M.-L. et al. Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. Febs. Lett. 580, 2414–2420 (2006).

Article CAS PubMed PubMed Central Google Scholar

de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).

Article PubMed PubMed Central Google Scholar

Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100–1115 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).

Article CAS PubMed PubMed Central Google Scholar

Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).

Article CAS PubMed PubMed Central Google Scholar

Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395, 507–513 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).

Article CAS PubMed PubMed Central Google Scholar

Chan, W., He, B., Wang, X. & He, M. L. Pandemic COVID-19: current status and challenges of antiviral therapies. Genes Dis. 7, 502–519 (2020).

Article CAS PubMed PubMed Central Google Scholar

Masters, P. S. The molecular biology of Coronaviruses. Adv. Virus Res 66, 193–292 (2006).

Article CAS PubMed PubMed Central Google Scholar

Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–450 (2009).

Article CAS PubMed PubMed Central Google Scholar

Zhou, F. et al. Attenuating innate immunity and facilitating beta-coronavirus infection by NSP1 of SARS-CoV-2 through specific redistributing hnRNP A2/B1 cellular localization. Signal Transduct. Target. Ther. 6, 371 (2021).

Article PubMed PubMed Central Google Scholar

Yang, H. & Rao, Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 19, 685–700 (2021).

Article CAS PubMed PubMed Central Google Scholar

Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93–116 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ruch, T. R. & Machamer, C. E. The coronavirus E protein: assembly and beyond. Viruses 4, 363–382 (2012).

Article CAS PubMed PubMed Central Google Scholar

V’Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).

Article PubMed Google Scholar

Satarker, S. & Nampoothiri, M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res. 51, 482–491 (2020).

Article CAS PubMed PubMed Central Google Scholar

Scherer, K. M. et al. SARS-CoV-2 nucleocapsid protein adheres to replication organelles before viral assembly at the Golgi/ERGIC and lysosome-mediated egress. Sci. Adv. 8, eabl4895 (2022).

Article CAS PubMed Google Scholar

Lu, X., Pan, J., Tao, J. & Guo, D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes 42, 37–45 (2011).

Article CAS PubMed Google Scholar

Li, F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237–261 (2016).

Article CAS PubMed PubMed Central Google Scholar

Romero-Brey, I. & Bartenschlager, R. Membranous replication factories induced by plus-strand RNA viruses. Viruses 6, 2826–2857 (2014).

Article CAS PubMed PubMed Central Google Scholar

Miller, S. & Krijnse-Locker, J. Modification of intracellular membrane structures for virus replication. Nat. Rev. Microbiol. 6, 363–374 (2008).

Article CAS PubMed PubMed Central Google Scholar

Cortese, M. et al. Integrative imaging reveals SARS-CoV-2-induced reshaping of subcellular morphologies. Cell Host Microbe 28, 853–866 (2020).

Article CAS PubMed PubMed Central Google Scholar

Snijder, E. J. et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J. Virol. 80, 5927–5940 (2006).

Article CAS PubMed PubMed Central Google Scholar

Wolff, G., Melia, C. E., Snijder, E. J. & Barcena, M. Double-membrane vesicles as platforms for viral replication. Trends Microbiol 28, 1022–1033 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wolff, G. et al. A molecular pore spans the double membrane of the coronavirus replication organelle. Science 369, 1395 (2020).

Article CAS PubMed PubMed Central Google Scholar

de Haan, C. A. M. & Rottier, P. J. M. Molecular interactions in the assembly of coronaviruses. Adv. Virus Res. 64, 165–230 (2005).

Article PubMed PubMed Central Google Scholar

Stertz, S. et al. The intracellular sites of early replication and budding of SARS-coronavirus. Virology 361, 304–315 (2007).

Article CAS PubMed Google Scholar

Ghosh, S. et al. beta-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183, 1520–1535.e1514 (2020).

Article CAS PubMed PubMed Central Google Scholar

Mendonca, L. et al. SARS-CoV-2 assembly and egress pathway revealed by correlative multi-modal multi-scale cryo-imaging. Preprint at bioRxiv https://doi.org/10.1101/2020.11.05.370239 (2020).

Strating, J. R. & van Kuppeveld, F. J. Viral rewiring of cellular lipid metabolism to create membranous replication compartments. Curr. Opin. Cell Biol. 47, 24–33 (2017).

Article CAS PubMed PubMed Central Google Scholar

Martin-Acebes, M. A., Vazquez-Calvo, A. & Saiz, J. C. Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses. Prog. Lipid Res. 64, 123–137 (2016).

Article CAS PubMed Google Scholar

Blaising, J. & Pecheur, E. I. Lipids: a key for hepatitis C virus entry and a potential target for antiviral strategies. Biochimie 95, 96–102 (2013).

Article CAS PubMed Google Scholar

Chan, R. B., Tanner, L. & Wenk, M. R. Implications for lipids during replication of enveloped viruses. Chem. Phys. Lipids 163, 449–459 (2010).

Article CAS PubMed PubMed Central Google Scholar

Altan-Bonnet, N. Lipid tales of viral replication and transmission. Trends Cell Biol. 27, 201–213 (2017).

Article CAS PubMed Google Scholar

Monson, E. A., Trenerry, A. M., Laws, J. L., Mackenzie, J. M. & Helbig, K. J. Lipid droplets and lipid mediators in viral infection and immunity. Fems. Microbiol. Rev. 45, fuaa066 (2021).

Article CAS PubMed PubMed Central Google Scholar

Monson, E. A., Whelan, D. R. & Helbig, K. J. Lipid droplet motility increases following viral immune stimulation. Int. J. Mol. Sci. 22, 4418 (2021).

Article CAS PubMed PubMed Central Google Scholar

Grootemaat, A. E. et al. Lipid and nucleocapsid N-protein accumulation in COVID-19 patient. Microbiol. Spectr. 10, e01271–21 (2022).

Article CAS PubMed PubMed Central Google Scholar

Nardacci, R. et al. Evidences for lipid involvement in SARS-CoV-2 cytopathogenesis. Cell Death Dis. 12, 263 (2021).

Article CAS PubMed PubMed Central Google Scholar

Song, J. W. et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 32, 188–202.e185 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wu, D. et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci. Rev. 7, 1157–1168 (2020).

Article CAS PubMed PubMed Central Google Scholar

Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell. Dev. Biol. 27, 441–464 (2011).

Article CAS PubMed Google Scholar

Zhu, L., Zhao, Q., Yang, T., Ding, W. & Zhao, Y. Cellular metabolism and macrophage functional polarization. Int. Rev. Immunol. 34, 82–100 (2015).

Article PubMed Google Scholar

Lee, A. H. & Dixit, V. D. Dietary regulation of immunity. Immunity 53, 510–523 (2020).

Article CAS PubMed PubMed Central Google Scholar

Kang, S. & Tang, H. HIV-1 infection and glucose metabolism reprogramming of T cells: another approach toward functional cure and reservoir eradication. Front. Immunol. 11, 572677 (2020).

Article CAS PubMed PubMed Central Google Scholar

Van den Bossche, J., O’Neill, L. A. & Menon, D. Macrophage immunometabolism: where are we going? Trends Immunol. 38, 395–406 (2017).

Article PubMed Google Scholar

Willig, A. L. & Overton, E. T. Metabolic complications and glucose metabolism in HIV infection: a review of the evidence. Curr. HIV/AIDS Rep. 13, 289–296 (2016).

Article PubMed PubMed Central Google Scholar

Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).

Article Google Scholar

Lim, S., Bae, J. H., Kwon, H. S. & Nauck, M. A. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. 17, 11–30 (2021).

Article CAS PubMed Google Scholar

Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhu, L. et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell metab. 31, 1068–1077.e1063 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhao, Q. et al. Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19. iScience 25, 105319 (2022).

Article CAS PubMed PubMed Central Google Scholar

Harding, J. L. et al. The bidirectional association between diabetes and long-COVID-19 - A systematic review. Diabetes Res. Clin. Pract. 195, 110202 (2022).

Article PubMed PubMed Central Google Scholar

Rey-Renones, C. et al. Type 2 diabetes mellitus and COVID-19: a narrative review. Biomedicines 10, 2089 (2022).

Article CAS PubMed PubMed Central Google Scholar

Gusev, E., Sarapultsev, A., Solomatina, L. & Chereshnev, V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. Int. J. Mol. Sci. 23, 1716 (2022).

Article CAS PubMed PubMed Central Google Scholar

Amraei, R. et al. CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2. Acs. Cent. Sci. 7, 1156–1165 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, S. et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 31, 126–140 (2021).

Article CAS PubMed Google Scholar

Koch, J. et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 40, e107821 (2021).

Article CAS PubMed PubMed Central Google Scholar

Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).

Article CAS PubMed PubMed Central Google Scholar

Beumer, J. et al. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. Nat. Commun. 12, 5498 (2021).

Article CAS PubMed PubMed Central Google Scholar

Kuhn, J. H., Li, W., Choe, H. & Farzan, M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol. Life. Sci. 61, 2738–2743 (2004).

Article CAS PubMed PubMed Central Google Scholar

Zhou, T. et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe 28, 867–879.e865 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wei, J. et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell 184, 76–91.e13 (2021).

Article CAS PubMed Google Scholar

Bayati, A., Kumar, R., Francis, V. & McPherson, P. S. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J. Biol. Chem. 296, 100306 (2021).

Article CAS PubMed PubMed Central Google Scholar

Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3–20 (2022).

Article CAS PubMed Google Scholar

Simons, K. & Sampaio, J. L. Membrane organization and lipid rafts. Cold Spring Harb. Perspect. Biol. 3, a004697 (2011).

Article PubMed PubMed Central Google Scholar

Sorice, M. et al. Targeting lipid rafts as a strategy against coronavirus. Front. Cell. Dev. Biol. 8, 618296 (2020).

Article PubMed Google Scholar

Fecchi, K. et al. Coronavirus interplay with lipid rafts and autophagy unveils promising therapeutic targets. Front. Microbiol. 11, 1821 (2020).

Article PubMed PubMed Central Google Scholar

Peruzzu, D. et al. Zika virus exploits lipid rafts to infect host cells. Viruses 14, 2059 (2022).

Article CAS PubMed PubMed Central Google Scholar

Palacios-Rapalo, S. N. et al. Cholesterol-rich lipid rafts as platforms for SARS-CoV-2 entry. Front. Immunol. 12, 796855 (2021).

Article CAS PubMed PubMed Central Google Scholar

Glende, J. et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology 381, 215–221 (2008).

Article CAS PubMed Google Scholar

Lu, Y., Liu, D. X. & Tam, J. P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 369, 344–349 (2008).

Article CAS PubMed PubMed Central Google Scholar

Warner, F. J. et al. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J. Biol. Chem. 280, 39353–39362 (2005).

Article CAS PubMed Google Scholar

Sim, J. R. et al. Amelioration of SARS-CoV-2 infection by ANO6 phospholipid scramblase inhibition. Cell Rep. 40, 111117 (2022).

Article CAS PubMed PubMed Central Google Scholar

George, K. S. & Wu, S. Lipid raft: a floating island of death or survival. Toxicol. Appl. Pharmacol. 259, 311–319 (2012).

Article CAS PubMed PubMed Central Google Scholar

Li, X. et al. Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification. Comput. Struct. Biotechnol. J. 19, 1933–1943 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, S. et al. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. EMBO J. 39, e106057 (2020).

Article CAS PubMed PubMed Central Google Scholar

Compton, A. A. & Schwartz, O. They might be giants: does syncytium formation sink or spread HIV infection? PLoS. Pathog. 13, e1006099 (2017).

Article PubMed PubMed Central Google Scholar

Duelli, D. & Lazebnik, Y. Cell-to-cell fusion as a link between viruses and Cancer. Nat. Rev. Cancer 7, 968–976 (2007).

Article CAS PubMed Google Scholar

Buchrieser, J. et al. Syncytia formation by SARS-CoV-2-infected cells. EMBO J. 39, e106267 (2020).

Article CAS PubMed PubMed Central Google Scholar

Sanders, D. W. et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. eLife 10, e65962 (2021).

Article CAS PubMed PubMed Central Google Scholar

Musarrat, F. et al. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J. Med. Virol. 92, 2087–2095 (2020).

Article CAS PubMed PubMed Central Google Scholar

Niyogi, K. & Hildreth, J. E. Characterization of new syncytium-inhibiting monoclonal antibodies implicates lipid rafts in human T-cell leukemia virus type 1 syncytium formation. J. Virol. 75, 7351–7361 (2001).

Article CAS PubMed PubMed Central Google Scholar

Wei, C. et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat. Metab. 2, 1391–1400 (2020).

Article CAS PubMed Google Scholar

Shen, W. J., Asthana, S., Kraemer, F. B. & Azhar, S. Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function. J. Lipid Res. 59, 1114–1131 (2018).

Article CAS PubMed PubMed Central Google Scholar

Correa, Y. et al. SARS-CoV-2 spike protein removes lipids from model membranes and interferes with the capacity of high density lipoprotein to exchange lipids. J. Colloid Interface Sci. 602, 732–739 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, R. et al. Genetic screens identify host factors for SARS-CoV-2 and common cold coronaviruses. Cell 184, 106–119.e114 (2021).

Article CAS PubMed Google Scholar

Daniloski, Z. et al. Identification of required host factors for SARS-CoV-2 infection in human. Cells Cell 184, 92–105.e116 (2021).

Article CAS PubMed Google Scholar

Campanero-Rhodes, M. A. et al. N-glycolyl GM1 ganglioside as a receptor for simian virus 40. J. Virol. 81, 12846–12858 (2007).

Article CAS PubMed PubMed Central Google Scholar

Miller, M. E., Adhikary, S., Kolokoltsov, A. A. & Davey, R. A. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J. Virol. 86, 7473–7483 (2012).

Article CAS PubMed PubMed Central Google Scholar

Hayashi, Y. et al. Sphingomyelin synthase 2, but not sphingomyelin synthase 1, is involved in HIV-1 envelope-mediated membrane fusion. J. Biol. Chem. 289, 30842–30856 (2014).

Article CAS PubMed PubMed Central Google Scholar

Aizaki, H. et al. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J. Virol. 82, 5715–5724 (2008).

Article CAS PubMed PubMed Central Google Scholar

Hannun, Y. A. & Obeid, L. M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 19, 175–191 (2018).

Article CAS PubMed Google Scholar

Vitner, E. B., Avraham, R., Politi, B., Melamed, S. & Israely, T. Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology. Life Sci. Alliance 5, e202101168 (2021).

Article PubMed PubMed Central Google Scholar

Torretta, T. E. et al. Severity of COVID-19 patients predicted by serum sphingolipids signature. Int. J. Mol. Sci. 22, 10198 (2021).

Article CAS PubMed PubMed Central Google Scholar

Carpinteiro, A. et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep. Med. 1, 100142 (2020).

Article CAS PubMed PubMed Central Google Scholar

Grassme, H. et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9, 322–330 (2003).

Article CAS PubMed Google Scholar

Grassme, H. et al. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276, 20589–20596 (2001).

Article CAS PubMed Google Scholar

Carpinteiro, A. et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J. Biol. Chem. 296, 100701 (2021).

Article CAS PubMed PubMed Central Google Scholar

Schloer, S. et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg. Microbes Infect. 9, 2245–2255 (2020).

Article CAS PubMed PubMed Central Google Scholar

Edwards, M. J. et al. Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. J. Biol. Chem. 295, 15174–15182 (2020).

Article CAS PubMed PubMed Central Google Scholar

Hoertel, N. et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. Mol. Psychiatry 26, 7098–7099 (2021).

Article CAS PubMed PubMed Central Google Scholar

Nguyen, L. et al. Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. Nat. Chem. Biol. 18, 81–90 (2022).

Article CAS PubMed Google Scholar

Fantini, J., Di Scala, C., Chahinian, H. & Yahi, N. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int. J. Antimicrob. Agents 55, 105960 (2020).

Article CAS PubMed PubMed Central Google Scholar

Yuan, Z., Pavel, M. A., Wang, H. & Hansen, S. B. Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry. Preprint at bioRxiv https://doi.org/10.1101/2020.08.13.250217 (2020).

Al-Bari, M. A. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J. Antimicrob. Chemother. 70, 1608–1621 (2015).

Article PubMed Google Scholar

Pastick, K. A. et al. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect. Dis. 7, ofaa130 (2020).

Article PubMed PubMed Central Google Scholar

Das, S. et al. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Med. Drug. Discov. 10, 100085 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zhang, Q., Wang, Y., Qi, C., Shen, L. & Li, J. Clinical trial analysis of 2019-nCoV therapy registered in China. J. Med. Virol. 92, 540–545 (2020).

Article CAS PubMed PubMed Central Google Scholar

Gao, J., Tian, Z. & Yang, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends 14, 72–73 (2020).

Article CAS PubMed Google Scholar

Brevini, T. et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615, 134–142 (2022).

Article PubMed PubMed Central Google Scholar

Feng, T. et al. Glycosylation of viral proteins: Implication in virus-host interaction and virulence. Virulence 13, 670–683 (2022).

Article CAS PubMed PubMed Central Google Scholar

Cheng, N. et al. Protein post-translational modification in SARS-CoV-2 and host interaction. Front. Immunol. 13, 1068449 (2022).

Article CAS PubMed Google Scholar

Tripathi, N., Goel, B., Bhardwaj, N., Vishwakarma, R. A. & Jain, S. K. Exploring the potential of chemical inhibitors for targeting post-translational glycosylation of coronavirus (SARS-CoV-2). ACS Omega 7, 27038–27051 (2022).

Article CAS PubMed PubMed Central Google Scholar

Tortorici, M. A. et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 26, 481–489 (2019).

Article PubMed PubMed Central Google Scholar

Yuan, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017).

Article CAS PubMed PubMed Central Google Scholar

Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260 (2020).

Article CAS PubMed PubMed Central Google Scholar

Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327–330 (2020).

Article CAS PubMed PubMed Central Google Scholar

Toelzer, C. et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science 370, 725 (2020).

Article CAS PubMed PubMed Central Google Scholar

Vivar-Sierra, A. et al. In silico study of polyunsaturated fatty acids as potential SARS-CoV-2 spike protein closed conformation stabilizers: epidemiological and computational approaches. Molecules 26, 711 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sofia, F. O. A. et al. The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour. Comput. Struct. Biotechnol. J. 20, 139–147 (2021).

Article Google Scholar

Li, X. et al. Protein palmitoylation modification during viral infection and detection methods of palmitoylated proteins. Front. Cell Infect. Microbiol. 12, 821596 (2022).

Article CAS PubMed PubMed Central Google Scholar

Abdulrahman, D. A., Meng, X. & Veit, M. S-Acylation of proteins of coronavirus and influenza virus: conservation of acylation sites in animal viruses and DHHC acyltransferases in their animal reservoirs. Pathogens 10, 669 (2021).

Article CAS PubMed PubMed Central Google Scholar

Yang, J. et al. Replication of murine coronavirus requires multiple cysteines in the endodomain of spike protein. Virology 427, 98–106 (2012).

Article CAS PubMed Google Scholar

Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science 370, 1089 (2021).

Article Google Scholar

Li, D., Liu, Y., Lu, Y., Gao, S. & Zhang, L. Palmitoylation of SARS-CoV-2 S protein is critical for S-mediated syncytia formation and virus entry. J. Med. Virol. 94, 342–348 (2022).

Article CAS PubMed Google Scholar

Wu, Z. et al. Palmitoylation of SARS-CoV-2 S protein is essential for viral infectivity. Signal Transduct. Target. Ther. 6, 231 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zeng, X. T., Yu, X. X. & Cheng, W. The interactions of ZDHHC5/GOLGA7 with SARS-CoV-2 spike (S) protein and their effects on S protein’s subcellular localization, palmitoylation and pseudovirus entry. Virol. J. 18, 257 (2021).

Article CAS PubMed PubMed Central Google Scholar

Mesquita, F. S. et al. S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity. Dev. Cell 56, 2790–2807.e2798 (2021).

Article CAS PubMed PubMed Central Google Scholar

Petit, C. M. et al. Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion. Virology 360, 264–274 (2007).

Article CAS PubMed Google Scholar

McBride, C. E. & Machamer, C. E. Palmitoylation of SARS-CoV S protein is necessary for partitioning into detergent-resistant membranes and cell-cell fusion but not interaction with M protein. Virology 405, 139–148 (2010).

Article CAS PubMed Google Scholar

Vargas-Rodriguez, J. R. et al. Sustained hyperglycemia and its relationship with the outcome of hospitalized patients with severe COVID-19: potential role of ACE2 upregulation. J. Pers. Med. 12, 805 (2022).

Article PubMed PubMed Central Google Scholar

Wysocki, J. et al. ACE and ACE2 activity in diabetic mice. Diabetes 55, 2132–2139 (2006).

Article CAS PubMed Google Scholar

Rao, S. T., Lau, A. & So, H. C. Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a Mendelian randomization analysis highlights tentative relevance of diabetes-related traits. Diabetes Care 43, 1416–1426 (2020).

Article CAS PubMed Google Scholar

Romani-Perez, M. et al. Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology 156, 3559–3569 (2015).

Article CAS PubMed Google Scholar

Zhang, W. et al. Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis. TheScientificWorldJournal 2014, 603409 (2014).

PubMed PubMed Central Google Scholar

Wosten-van Asperen, R. M. et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J. Pathol. 225, 618–627 (2011).

Article PubMed Google Scholar

Ferrario, C. M. et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111, 2605–2610 (2005).

Article CAS PubMed Google Scholar

Zou, X. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 14, 185–192 (2020).

Article PubMed PubMed Central Google Scholar

Lukassen, S. et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 39, e105114 (2020).

Article CAS PubMed PubMed Central Google Scholar

Garreta, E. et al. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metab. 34, 857–873.e859 (2022).

Article CAS PubMed PubMed Central Google Scholar

Vigerust, D. J. & Shepherd, V. L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 15, 211–218 (2007).

Article CAS PubMed PubMed Central Google Scholar

Yang, T. J. et al. Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans. Proc. Natl Acad. Sci. USA 117, 1438–1446 (2020).

Article CAS PubMed PubMed Central Google Scholar

Walls, A. C. et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat. Struct. Mol. Biol. 23, 899–905 (2016).

Article CAS PubMed PubMed Central Google Scholar

Watanabe, Y. et al. Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nat. Commun. 11, 2688 (2020).

Article CAS PubMed PubMed Central Google Scholar

Shajahan, A., Supekar, N. T., Gleinich, A. S. & Azadi, P. Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 30, 981–988 (2020).

Article CAS PubMed PubMed Central Google Scholar

Sanda, M., Morrison, L. & Goldman, R. N- and O-glycosylation of the SARS-CoV-2 spike protein. Anal. Chem. 93, 2003–2009 (2021).

Article CAS PubMed Google Scholar

Zhou, D., Tian, X., Qi, R., Peng, C. & Zhang, W. Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics. Glycobiology 31, 69–80 (2021).

CAS PubMed Google Scholar

Antonopoulos, A. et al. Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain. Glycobiology 31, 181–187 (2021).

Article CAS PubMed Google Scholar

Watanabe, Y. et al. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330 (2020).

Article CAS PubMed PubMed Central Google Scholar

Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–1294.e1289 (2020).

Article CAS PubMed PubMed Central Google Scholar

Casalino, L. et al. Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein. ACS Cent. Sci. 6, 1722–1734 (2020).

Article CAS PubMed PubMed Central Google Scholar

Huang, H. C. et al. Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. EBioMedicine 74, 103712 (2021).

Article CAS PubMed PubMed Central Google Scholar

Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779–784.e775 (2020).

Article CAS PubMed PubMed Central Google Scholar

Cheng, Y. W. et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 33, 108254 (2020).

Article CAS PubMed PubMed Central Google Scholar

Yang, Q. et al. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration. Elife 9, e61552 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, L. et al. Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation. Proc. Natl Acad. Sci. USA 118, e2109905118 (2021).

Article CAS PubMed PubMed Central Google Scholar

Thaker, S. K., Ch’ng, J. & Christofk, H. R. Viral hijacking of cellular metabolism. BMC Biol. 17, 59 (2019).

Article PubMed PubMed Central Google Scholar

Twu, W. I. et al. Contribution of autophagy machinery factors to HCV and SARS-CoV-2 replication organelle formation. Cell Rep. 37, 110049 (2021).

Article CAS PubMed PubMed Central Google Scholar

Koepke, L., Hirschenberger, M., Hayn, M., Kirchhoff, F. & Sparrer, K. M. Manipulation of autophagy by SARS-CoV-2 proteins. Autophagy 17, 2659–2661 (2021).

Article CAS PubMed PubMed Central Google Scholar

Miao, G. et al. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation. Dev. Cell 56, 427–442.e425 (2021).

Article CAS PubMed Google Scholar

Gassen, N. C. et al. SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection. Nat. Commun. 10, 5770 (2019).

Article CAS PubMed PubMed Central Google Scholar

Gassen, N. C. et al. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat. Commun. 12, 3818 (2021).

Article CAS PubMed PubMed Central Google Scholar

Delorme-Axford, E. & Klionsky, D. J. Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection? Autophagy 16, 2123–2127 (2020).

Article CAS PubMed PubMed Central Google Scholar

Miller, K. et al. Coronavirus interactions with the cellular autophagy machinery. Autophagy 16, 2131–2139 (2020).

Article CAS PubMed PubMed Central Google Scholar

Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell. Biol. 23, 21–39 (2022).

Article CAS PubMed Google Scholar

Pombo, J. P. & Sanyal, S. Perturbation of intracellular cholesterol and fatty acid homeostasis during flavivirus infections. Front. Immunol. 9, 1276 (2018).

Article PubMed PubMed Central Google Scholar

Yan, B. et al. Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication. Viruses 11, 73 (2019).

Article CAS PubMed PubMed Central Google Scholar

Heaton, N. S. & Randall, G. Multifaceted roles for lipids in viral infection. Trends Microbiol. 19, 368–375 (2011).

Article CAS PubMed PubMed Central Google Scholar

Moriel-Carretero, M. The hypothetical role of phosphatidic acid in subverting ER membranes during SARS-CoV infection. Traffic 21, 545–551 (2020).

Article CAS PubMed PubMed Central Google Scholar

Tabata, K. et al. Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation. Nat. Commun. 12, 7276 (2021).

Article CAS PubMed PubMed Central Google Scholar

Yan, B. et al. Phosphatidic acid phosphatase 1 impairs SARS-CoV-2 replication by affecting the glycerophospholipid metabolism pathway. Int. J. Biol. Sci. 18, 4744–4755 (2022).

Article CAS PubMed PubMed Central Google Scholar

Xu, K. & Nagy, P. D. RNA virus replication depends on enrichment of phosphatidylethanolamine at replication sites in subcellular membranes. Proc. Natl Acad. Sci. USA 112, E1782–E1791 (2015).

Article CAS PubMed PubMed Central Google Scholar

Xu, K. & Nagy, P. D. Enrichment of phosphatidylethanolamine in viral replication compartments via co-opting the endosomal Rab5 small GTPase by a positive-strand RNA virus. PLoS Biol. 14, e2000128 (2016).

Article PubMed PubMed Central Google Scholar

Belov, G. A. Less grease, please. phosphatidylethanolamine is the only lipid required for replication of a (+)RNA virus. Viruses 7, 3500–3505 (2015).

Article CAS PubMed PubMed Central Google Scholar

Huang, Q., Lei, H., Ding, L. & Wang, Y. Stimulated phospholipid synthesis is key for hepatitis B virus replications. Sci. Rep. 9, 12989 (2019).

Article PubMed PubMed Central Google Scholar

He, G. et al. An engineered mutant of a host phospholipid synthesis gene inhibits viral replication without compromising host fitness. J. Biol. Chem. 294, 13973–13982 (2019).

Article CAS PubMed PubMed Central Google Scholar

Williams, C. G. et al. Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication. Cell Rep. 36, 109479 (2021).

Article CAS PubMed PubMed Central Google Scholar

Chu, J. et al. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication. Nat. Metab. 3, 1466–1475 (2021).

Article CAS PubMed PubMed Central Google Scholar

Heaton, N. S. et al. Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc. Natl Acad. Sci. USA 107, 17345–17350 (2010).

Article CAS PubMed PubMed Central Google Scholar

Martin-Acebes, M. A., Jimenez de Oya, N. & Saiz, J. C. Lipid metabolism as a source of druggable targets for antiviral discovery against Zika and other flaviviruses. Pharmaceuticals 12, 97 (2019).

Article CAS PubMed PubMed Central Google Scholar

Crawford, S. E. & Desselberger, U. Lipid droplets form complexes with viroplasms and are crucial for rotavirus replication. Curr. Opin. Virol. 19, 11–15 (2016).

Article CAS PubMed PubMed Central Google Scholar

Saka, H. A. & Valdivia, R. Emerging roles for lipid droplets in immunity and host-pathogen interactions. Annu. Rev. Cell. Dev. Biol. 28, 411–437 (2012).

Article CAS PubMed Google Scholar

Zhang, J., Lan, Y. & Sanyal, S. Modulation of lipid droplet metabolism-A potential target for therapeutic intervention in Flaviviridae infections. Front. Microbiol. 8, 2286 (2017).

Article PubMed PubMed Central Google Scholar

Cermelli, S., Guo, Y., Gross, S. P. & Welte, M. A. The lipid-droplet proteome reveals that droplets are a protein-storage depot. Curr. Biol. 16, 1783–1795 (2006).

Article CAS PubMed Google Scholar

Farese, R. V. Jr. & Walther, T. C. Lipid droplets finally get a little R-E-S-P-E-C-T. Cell 139, 855–860 (2009).

Article CAS PubMed PubMed Central Google Scholar

Pol, A., Gross, S. P. & Parton, R. G. Review: biogenesis of the multifunctional lipid droplet: lipids, proteins, and sites. J. Cell Biol. 204, 635–646 (2014).

Article CAS PubMed PubMed Central Google Scholar

Olzmann, J. A. & Carvalho, P. Dynamics and functions of lipid droplets. Nat. Rev. Mol. Cell. Biol. 20, 137–155 (2019).

Article CAS PubMed PubMed Central Google Scholar

Pagliari, F. et al. ssRNA virus and host lipid rearrangements: is there a role for lipid droplets in SARS-CoV-2 infection? Front. Mol. Biosci. 7, 578964 (2020).

Article CAS PubMed PubMed Central Google Scholar

Dias, S. S. G. et al. Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators. PLoS Pathog. 16, e1009127 (2020).

Article CAS PubMed PubMed Central Google Scholar

Yuan, S. et al. SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discov. 7, 100 (2021).

Article PubMed PubMed Central Google Scholar

Fonnesu, R. et al. Palmitoylethanolamide (PEA) inhibits SARS-CoV-2 entry by interacting with S protein and ACE-2 receptor. Viruses 14, 1080 (2022).

Article CAS PubMed PubMed Central Google Scholar

Ricciardi, S. et al. The role of NSP6 in the biogenesis of the SARS-CoV-2 replication organelle. Nature 606, 761–768 (2022).

Article CAS PubMed PubMed Central Google Scholar

Moretti, F. et al. TMEM41B is a novel regulator of autophagy and lipid mobilization. EMBO Rep. 19, e45889 (2018).

Article PubMed PubMed Central Google Scholar

Li, Y. E. et al. TMEM41B and VMP1 are scramblases and regulate the distribution of cholesterol and phosphatidylserine. J. Cell Biol. 220, e202103105 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sun, L. et al. Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication. PLoS Pathog. 17, e1010113 (2021).

Article CAS PubMed PubMed Central Google Scholar

Ji, M. et al. VMP1 and TMEM41B are essential for DMV formation during beta-coronavirus infection. J. Cell Biol. 221, e202112081 (2022).

Article PubMed PubMed Central Google Scholar

Shoemaker, C. J. et al. CRISPR screening using an expanded toolkit of autophagy reporters identifies TMEM41B as a novel autophagy factor. PLoS Biol. 17, e2007044 (2019).

Article CAS PubMed PubMed Central Google Scholar

Morita, K. et al. Genome-wide CRISPR screen identifies TMEM41B as a gene required for autophagosome formation. J. Cell Biol. 217, 3817–3828 (2018).

Article CAS PubMed PubMed Central Google Scholar

Schneider, W. M. et al. Genome-scale identification of SARS-CoV-2 and Pan-coronavirus host factor networks. Cell 184, 120–132.e114 (2021).

Article CAS PubMed Google Scholar

Trimarco, J. D. et al. TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. PLoS pathog. 17, e1009599 (2021).

Article CAS PubMed PubMed Central Google Scholar

Kratzel, A. et al. A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets. PLoS Biol. 19, e3001490 (2021).

Article CAS PubMed PubMed Central Google Scholar

Icard, P. et al. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie 180, 169–177 (2021).

Article CAS PubMed Google Scholar

Roy, S. & Demmer, R. T. Impaired glucose regulation, SARS-CoV-2 infections and adverse COVID-19 outcomes. Transl. Res. 241, 52–69 (2022).

Article CAS PubMed Google Scholar

Montefusco, L. et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 3, 774–785 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sanchez, E. L. & Lagunoff, M. Viral activation of cellular metabolism. Virology 479, 609–618 (2015).

Article PubMed Google Scholar

Singh, S. et al. AMP-activated protein kinase restricts Zika virus replication in endothelial cells by potentiating innate antiviral responses and inhibiting glycolysis. J. Immunol. 204, 1810–1824 (2020).

Article CAS PubMed Google Scholar

Zhang, Y. et al. SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. Nat. Commun. 12, 1676 (2021).

Article CAS PubMed PubMed Central Google Scholar

Bojkova, D. et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature 583, 469–472 (2020).

Article CAS PubMed Google Scholar

Codo, A. C. et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 32, 437–446.e435 (2020).

Article CAS PubMed PubMed Central Google Scholar

Duan, X. et al. An airway organoid-based screen identifies a role for the HIF1alpha-glycolysis axis in SARS-CoV-2 infection. Cell Rep. 37, 109920 (2021).

Article CAS PubMed PubMed Central Google Scholar

Stincone, A. et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol. Rev. Camb. Philos. Soc. 90, 927–963 (2015).

Article PubMed Google Scholar

Jiang, P., Du, W. & Wu, M. Regulation of the pentose phosphate pathway in cancer. Protein Cell 5, 592–602 (2014).

Article CAS PubMed PubMed Central Google Scholar

Santos, E. S. J. C. et al. Gene signatures of autopsy lungs from obese patients with COVID-19. Clin. Nutr. Espen. 44, 475–478 (2021).

Article Google Scholar

Bojkova, D. et al. Targeting the pentose phosphate pathway for SARS-CoV-2 therapy. Metabolites 11, 699 (2021).

Article CAS PubMed PubMed Central Google Scholar

Ducker, G. S. & Rabinowitz, J. D. One-carbon metabolism in health and disease. Cell Metab. 25, 27–42 (2017).

Article CAS PubMed Google Scholar

Hiraoka, M. & Kagawa, Y. Genetic polymorphisms and folate status. Congenit. Anom. 57, 142–149 (2017).

Article CAS Google Scholar

Decroly, E., Ferron, F., Lescar, J. & Canard, B. Conventional and unconventional mechanisms for capping viral mRNA. Nat. Rev. Microbiol. 10, 51–65 (2011).

Article PubMed PubMed Central Google Scholar

Chen, Y. & Guo, D. Molecular mechanisms of coronavirus RNA capping and methylation. Virol. Sin. 31, 3–11 (2016).

Article CAS PubMed PubMed Central Google Scholar

Sevajol, M., Subissi, L., Decroly, E., Canard, B. & Imbert, I. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Res. 194, 90–99 (2014).

Article CAS PubMed Google Scholar

Mandilara, G. et al. The role of coronavirus RNA-processing enzymes in innate immune evasion. Life (Basel) 11, 571 (2021).

CAS PubMed Google Scholar

Yan, L. et al. Coupling of N7-methyltransferase and 3’-5’ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell 184, 3474–3485 e3411 (2021).

Article CAS PubMed PubMed Central Google Scholar

Romano, M., Ruggiero, A., Squeglia, F., Maga, G. & Berisio, R. A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells 9, 1267 (2020).

Article CAS PubMed PubMed Central Google Scholar

Mentch, S. J. & Locasale, J. W. One-carbon metabolism and epigenetics: understanding the specificity. Ann. N. Y. Acad. Sci. 1363, 91–98 (2016).

Article CAS PubMed Google Scholar

Bergant, V. et al. Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2’-O-ribose methyltransferases. EMBO J. 41, e111608 (2022).

Article CAS PubMed PubMed Central Google Scholar

Jack, A. et al. SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA. PLoS Biol. 19, e3001425 (2021).

Article CAS PubMed PubMed Central Google Scholar

Luo, H. et al. Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction. Int. J. Biochem. Cell Biol. 38, 589–599 (2006).

Article CAS PubMed Google Scholar

Neuman, B. W. et al. A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol. 174, 11–22 (2011).

Article CAS PubMed Google Scholar

Thomas, S. The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog. Immun. 5, 342–363 (2020).

Article PubMed PubMed Central Google Scholar

Mortola, E. & Roy, P. Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system. FEBS Lett. 576, 174–178 (2004).

Article CAS PubMed PubMed Central Google Scholar

Corse, E. & Machamer, C. E. The cytoplasmic tails of infectious bronchitis virus E and M proteins mediate their interaction. Virology 312, 25–34 (2003).

Article CAS PubMed Google Scholar

Baudoux, P. et al. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J. Virol. 72, 8636–8643 (1998).

Article CAS PubMed PubMed Central Google Scholar

Yuan, Z. et al. The E3 ubiquitin ligase RNF5 facilitates SARS-CoV-2 membrane protein-mediated virion release. MBIO 13, e03168–21 (2022).

Article CAS PubMed Central Google Scholar

Cabrera-Garcia, D. et al. The envelope protein of SARS-CoV-2 increases intra-Golgi pH and forms a cation channel that is regulated by pH. J. Physiol. 599, 2851–2861 (2021).

Article CAS PubMed Google Scholar

Boson, B. et al. The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. J. Biol. Chem. 296, 100111 (2021).

Article CAS PubMed Google Scholar

Eymieux, S. et al. Secretory vesicles are the principal means of SARS-CoV-2 Egress. Cells 10, 2047 (2021).

Article CAS PubMed PubMed Central Google Scholar

Monje-Galvan, V. & Voth, G. A. Molecular interactions of the M and E integral membrane proteins of SARS-CoV-2. bioRxiv (2021).

Raamsman, M. J. B. et al. Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E. J. Viol. 74, 2333–2342 (2000).

CAS Google Scholar

Veit, M. Palmitoylation of virus proteins. Biol. Cell 104, 493–515 (2012).

Article CAS PubMed PubMed Central Google Scholar

Li, M., Yang, C., Tong, S., Weidmann, A. & Compans, R. W. Palmitoylation of the murine leukemia virus envelope protein is critical for lipid raft association and surface expression. J. Virol. 76, 11845–11852 (2002).

Article CAS PubMed PubMed Central Google Scholar

Boscarino, J. A., Logan, H. L., Lacny, J. J. & Gallagher, T. M. Envelope protein palmitoylations are crucial for murine coronavirus assembly. J. Virol. 82, 2989–2999 (2008).

Article CAS PubMed PubMed Central Google Scholar

Resh, M. D. Fatty acylation of proteins: the long and the short of it. Prog. Lipid Res. 63, 120–131 (2016).

Article CAS PubMed PubMed Central Google Scholar

Rana, M. S., Lee, C. J. & Banerjee, A. The molecular mechanism of DHHC protein acyltransferases. Biochem. Soc. Trans. 47, 157–167 (2019).

Article CAS PubMed Google Scholar

Lopez, L. A., Riffle, A. J., Pike, S. L., Gardner, D. & Hogue, B. G. Importance of conserved cysteine residues in the coronavirus envelope protein. J. Virol. 82, 3000–3010 (2008).

Article CAS PubMed PubMed Central Google Scholar

Liao, Y., Yuan, Q., Torres, J., Tam, J. P. & Liu, D. X. Biochemical and functional characterization of the membrane association and membrane permeabilizing activity of the severe acute respiratory syndrome coronavirus envelope protein. Virology 349, 264–275 (2006).

Article CAS PubMed Google Scholar

Sun, S. et al. Computational study on the function of palmitoylation on the envelope protein in SARS-CoV-2. J. Chem. Theory Comput. 17, 6483–6490 (2021).

Article CAS PubMed Google Scholar

Kuzmin, A., Orekhov, P., Astashkin, R., Gordeliy, V. & Gushchin, I. Structure and dynamics of the SARS-CoV-2 envelope protein monomer. Proteins 90, 1102–1114 (2022).

Article CAS PubMed Google Scholar

Wei, Y. et al. Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: an epidemiological study from a fever clinic in Wuhan, China. J. Med. Virol. 92, 2758–2767 (2020).

Article CAS PubMed PubMed Central Google Scholar

Lo, M. W., Kemper, C. & Woodruff, T. M. COVID-19: complement, coagulation, and collateral damage. J. Immunol. 205, 1488–1495 (2020).

Article CAS PubMed Google Scholar

Qin, C. et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020).

Article CAS PubMed Google Scholar

Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e1039 (2020).

Article CAS PubMed PubMed Central Google Scholar

Wang, Y., Wu, M., Li, Y., Yuen, H. H. & He, M. L. The effects of SARS-CoV-2 infection on modulating innate immunity and strategies of combating inflammatory response for COVID-19 therapy. J. Biomed. Sci. 29, 27 (2022).

Article PubMed PubMed Central Google Scholar

Kouwaki, T., Nishimura, T., Wang, G. & Oshiumi, H. RIG-I-like receptor-mediated recognition of viral genomic RNA of severe acute respiratory syndrome coronavirus-2 and viral escape from the host innate immune responses. Front. Immunol. 12, 700926 (2021).

Article CAS PubMed PubMed Central Google Scholar

Aboudounya, M. M. & Heads, R. J. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat. Inflamm. 2021, 8874339 (2021).

Article Google Scholar

Rodrigues, T. S. et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 218, e20201707 (2021).

Article CAS PubMed Google Scholar

Toldo, S. et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm. Res. 70, 7–10 (2021).

Article CAS PubMed Google Scholar

Wu, B. et al. ORAI1 limits SARS-CoV-2 infection by regulating tonic type I IFN signaling. J. Immunol. 208, 74–84 (2022).

Article CAS PubMed Google Scholar

Quarleri, J. & Delpino, M. V. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine Growth Factor Rev. 58, 55–65 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lamers, M. M. & Haagmans, B. L. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 20, 270–284 (2022).

Article CAS PubMed Google Scholar

Zheng, B. J. et al. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha beta) but not by type II interferon (IFN-gamma). J. Interf. Cytok. Res. 24, 388–390 (2004).

Article CAS Google Scholar

Yongzhi, X. COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. Emerg. Microbes Infect. 10, 266–276 (2021).

Article PubMed PubMed Central Google Scholar

Olbei, M. et al. SARS-CoV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely Ill patients. Front. Immunol. 12, 629193 (2021).

Article CAS PubMed PubMed Central Google Scholar

Karki, R. et al. Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168.e117 (2021).

Article CAS PubMed Google Scholar

Zhou, Y. G. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci. Rev. 7, 998–1002 (2020).

Article PubMed PubMed Central Google Scholar

Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 130, 2620–2629 (2020).

Article CAS PubMed PubMed Central Google Scholar

Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).

Article CAS PubMed PubMed Central Google Scholar

Dolhnikoff, M. et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J. Thromb. Haemost. 18, 1517–1519 (2020).

Article CAS PubMed PubMed Central Google Scholar

Menter, T. et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77, 198–209 (2020).

Article PubMed PubMed Central Google Scholar

Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 383, 120–128 (2020).

Article CAS PubMed PubMed Central Google Scholar

Gu, S. X. et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 18, 194–209 (2021).

Article CAS PubMed Google Scholar

Villar, J. et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 8, 267–276 (2020).

Article CAS PubMed Google Scholar

Group, R. C. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704 (2021).

Article Google Scholar

Ehrmann, S. et al. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir. Med. 9, 1387–1395 (2021).

Article CAS PubMed PubMed Central Google Scholar

Zaid, Y. et al. Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. J. Allergy Clin. Immunol. 148, 368–380.e363 (2021).

Article CAS PubMed PubMed Central Google Scholar

Kuypers, F. A. et al. Secretory phospholipase A2 in SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C). Exp. Biol. Med. 246, 2543–2552 (2021).

Article CAS Google Scholar

Kott, M. et al. Acid Sphingomyelinase Serum Activity Predicts Mortality in Intensive Care Unit Patients after Systemic Inflammation: A Prospective Cohort Study. PLoS ONE 9, e112323 (2014).

Article PubMed PubMed Central Google Scholar

Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986–1000 (2011).

Article CAS PubMed PubMed Central Google Scholar

Chen, J. S. et al. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. Preprint at bioRxiv https://doi.org/10.1101/2020.09.24.312769 (2020).

Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target. Ther. 5, 33 (2020).

Article CAS PubMed PubMed Central Google Scholar

Ricke-Hoch, M. et al. Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE 16, e0255335 (2021).

Article CAS PubMed PubMed Central Google Scholar

Aliabadi, F., Ajami, M. & Pazoki-Toroudi, H. Why does COVID-19 pathology have several clinical forms? BioEssays 42, e2000198 (2020).

Article PubMed Google Scholar

Gupta, A. & Chander Chiang, K. Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease. Med. Hypotheses 143, 110122 (2020).

Article CAS PubMed PubMed Central Google Scholar

Serhan, C. N., Chiang, N. & Van Dyke, T. E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8, 349–361 (2008).

Article CAS PubMed PubMed Central Google Scholar

Manne, B. K. et al. Platelet gene expression and function in patients with COVID-19. Blood 136, 1317–1329 (2020).

Article CAS PubMed Google Scholar

Manne, B. K. et al. PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway. J. Thromb. Haemost. 16, 1211–1225 (2018).

Article CAS PubMed PubMed Central Google Scholar

Gelfand, E. W. Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma. Semin. Immunol. 33, 44–51 (2017).

Article CAS PubMed PubMed Central Google Scholar

Hashimoto, K. et al. Cysteinyl leukotrienes induce monocyte chemoattractant protein-1 in human monocyte/macrophages via mitogen-activated protein kinase and nuclear factor-kappaB pathways. Int. Arch. Allergy Immunol. 149, 275–282 (2009).

Article CAS PubMed Google Scholar

Goodarzi, K., Goodarzi, M., Tager, A. M., Luster, A. D. & von Andrian, U. H. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat. Immunol. 4, 965–973 (2003).

Article CAS PubMed Google Scholar

Di Gennaro, A. & Haeggstrom, J. Z. The leukotrienes: immune-modulating lipid mediators of disease. Adv. Immunol. 116, 51–92 (2012).

Article PubMed Google Scholar

Kong, M., Zhang, H., Cao, X., Mao, X. & Lu, Z. Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19. Epidemiol. Infect. 148, e139 (2020).

Article PubMed Google Scholar

Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070–1076 (2020).

Article CAS PubMed PubMed Central Google Scholar

Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842–844 (2020).

Article CAS PubMed Google Scholar

Huang, L. et al. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler. Thromb. Vasc. Biol. 24, 1783–1788 (2004).

Article CAS PubMed Google Scholar

Brach, M. A. et al. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-xB and NF-IL6. Eur. J. Immunol. 22, 2705–2711 (1992).

Article CAS PubMed Google Scholar

Liu, T. et al. Cysteinyl leukotriene receptor 2 drives lung immunopathology through a platelet and high mobility box 1-dependent mechanism. Mucosal Immunol. 12, 679–690 (2019).

Article CAS PubMed PubMed Central Google Scholar

Cummings, H. E. et al. Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J. Immunol. 191, 5807–5810 (2013).

Article CAS PubMed Google Scholar

Xu, X. et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur. J. Nucl. Med. Mol. Imaging 47, 1275–1280 (2020).

Article CAS PubMed PubMed Central Google Scholar

Archambault, A. S. et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. Faseb J. 35, e21666 (2021).

Article CAS PubMed Google Scholar

Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 50, S52–S56 (2009).

Article PubMed PubMed Central Google Scholar

Gilroy, D. W. et al. CYP450-derived oxylipins mediate inflammatory resolution. Proc. Natl Acad. Sci. USA 113, E3240–E3249 (2016).

Article CAS PubMed PubMed Central Google Scholar

Deng, Y. et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J. 25, 703–713 (2011).

Article CAS PubMed PubMed Central Google Scholar

Zhou, Y. et al. Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice. Shock 47, 638–645 (2017).

Article CAS PubMed PubMed Central Google Scholar

Arshad, H. et al. Decreased plasma phospholipid concentrations and increased acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. J. Transl. Med. 17, 365 (2019).

Article PubMed PubMed Central Google Scholar

Beckmann, N. et al. Regulation of arthritis severity by the acid sphingomyelinase. Cell Physiol. Biochem. 43, 1460–1471 (2017).

Article CAS PubMed Google Scholar

Chung, H. Y. et al. Acid sphingomyelinase promotes endothelial stress response in systemic inflammation and sepsis. Mol. Med. 22, 412–423 (2016).

Article CAS PubMed PubMed Central Google Scholar

Pandolfi, R. et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax 72, 460–471 (2017).

Article PubMed Google Scholar

Berkman, S. A. & Tapson, V. F. COVID-19 and its implications for thrombosis and anticoagulation. Semin. Respir. Crit. Care Med. 42, 316–326 (2021).

Article PubMed Google Scholar

Grover, S. P. & Mackman, N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol. 38, 709–725 (2018).

Article CAS PubMed Google Scholar

Wang, J. et al. SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase. Blood 138, 344–349 (2021).

Article CAS PubMed PubMed Central Google Scholar

Abusukhun, M. et al. Activation of sphingomyelinase-ceramide-pathway in COVID-19 purposes its inhibition for therapeutic strategies. Front. Immunol. 12, 784989 (2021).

Article CAS PubMed PubMed Central Google Scholar

Mostaza, J. M. et al. Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2. Atherosclerosis 341, 13–19 (2022).

Article CAS PubMed Google Scholar

Hilser, J. R. et al. Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection. J. Lipid Res. 62, 100061 (2021).

Article CAS PubMed PubMed Central Google Scholar

Masana, L. et al. Low HDL and high triglycerides predict COVID-19 severity. Sci. Rep. 11, 7217 (2021).

Article CAS PubMed PubMed Central Google Scholar

Peng, F., Lei, S., Zhang, Q., Zhong, Y. & Wu, S. Triglyceride/high-density lipoprotein cholesterol ratio is associated with the mortality of COVID-19: a retrospective study in China. Int. J. Gen. Med. 15, 985–996 (2022).

Article CAS PubMed PubMed Central Google Scholar

Groenen, A. G., Halmos, B., Tall, A. R. & Westerterp, M. Cholesterol efflux pathways, inflammation, and atherosclerosis. Crit. Rev. Biochem. Mol. Biol. 56, 426–439 (2021).

Article CAS PubMed PubMed Central Google Scholar

Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104–116 (2015).

Article CAS PubMed PubMed Central Google Scholar

de la Roche, M. et al. Trafficking of cholesterol to the ER is required for NLRP3 inflammasome activation. J. Cell Biol. 217, 3560–3576 (2018).

Article PubMed PubMed Central Google Scholar

Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20, 3328 (2019).

Article CAS PubMed PubMed Central Google Scholar

Cardoso, D. & Perucha, E. Cholesterol metabolism: a new molecular switch to control inflammation. Clin. Sci. 135, 1389–1408 (2021).

Article CAS Google Scholar

Radhakrishnan, A., Goldstein, J. L., McDonald, J. G. & Brown, M. S. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 8, 512–521 (2008).

Article CAS PubMed PubMed Central Google Scholar

Guo, C. et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 49, 842–856.e847 (2018).

Article CAS PubMed Google Scholar

Li, L. C. et al. Cross-talk between TLR4-MyD88-NF-kappaB and SCAP-SREBP2 pathways mediates macrophage foam cell formation. Am. J. Physiol. Heart Circ. Physiol. 304, H874–H884 (2013).

Article CAS PubMed Google Scholar

Kusnadi, A. et al. The cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair. Immunity 51, 241–257.e249 (2019).

Article CAS PubMed PubMed Central Google Scholar

Lee, W. et al. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Signal Transduct. Target. Ther. 5, 186 (2020).

Article CAS PubMed PubMed Central Google Scholar

Navab, M., Anantharamaiah, G. M. & Fogelman, A. M. The role of high-density lipoprotein in inflammation. Trends Cardiovasc. Med. 15, 158–161 (2005).

Article CAS PubMed Google Scholar

Samadi, S. et al. Human T lymphotropic virus type 1 and risk of cardiovascular disease: high-density lipoprotein dysfunction versus serum HDL-C concentrations. Biofactors 45, 374–380 (2019).

Article CAS PubMed PubMed Central Google Scholar

Meilhac, O., Tanaka, S. & Couret, D. High-density lipoproteins are bug scavengers. Biomolecules 10, 598 (2020).

Article CAS PubMed PubMed Central Google Scholar

Stasi, A. et al. Multifaced roles of HDL in sepsis and SARS-CoV-2 infection: renal implications. Int. J. Mol. Sci. 22, 5980 (2021).

Article CAS PubMed PubMed Central Google Scholar

Gao, Y. D. et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76, 428–455 (2021).

Article CAS PubMed Google Scholar

Chea, N. et al. Risk factors for SARS-CoV-2 infection among US healthcare personnel, May-December 2020. Emerg. Infect. Dis. 28, 95–103 (2022).

Article CAS PubMed PubMed Central Google Scholar

Wu, C. T. et al. SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 33, 1565–1576 e1565 (2021).

Article CAS PubMed PubMed Central Google Scholar

Shaharuddin, S. H. et al. Deleterious effects of SARS-CoV-2 infection on human pancreatic cells. Front. Cell Infect. Microbiol. 11, 678482 (2021).

Article CAS PubMed PubMed Central Google Scholar

Liu, F. et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin. Gastroenterol. Hepatol. 18, 2128–2130.e2122 (2020).

Article CAS PubMed PubMed Central Google Scholar

Khunti, K. et al. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care 44, 2645–2655 (2021).

Article CAS PubMed PubMed Central Google Scholar

Donath, M. Y., Dinarello, C. A. & Mandrup-Poulsen, T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat. Rev. Immunol. 19, 734–746 (2019).

Article CAS PubMed Google Scholar

Esposito, K. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106, 2067–2072 (2002).

Article CAS PubMed Google Scholar

Hu, R., Xia, C. Q., Butfiloski, E. & Clare-Salzler, M. Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection. Clin. Immunol. 195, 139–148 (2018).

Article CAS PubMed PubMed Central Google Scholar

Guo, W. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 36, e3319 (2020).

Article CAS PubMed PubMed Central Google Scholar

Quinn, W. J. 3rd et al. Lactate limits T cell proliferation via the NAD(H) redox state. Cell Rep. 33, 108500 (2020).

Article CAS PubMed PubMed Central Google Scholar

Manosalva, C. et al. Role of lactate in inflammatory processes: friend or foe. Front. Immunol. 12, 808799 (2021).

Article CAS PubMed Google Scholar

Pucino, V. et al. Lactate buildup at the site of chronic inflammation promotes disease by inducing CD4(+) T cell metabolic rewiring. Cell Metab. 30, 1055–1074.e1058 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ivashkiv, L. B. The hypoxia-lactate axis tempers inflammation. Nat. Rev. Immunol. 20, 85–86 (2020).

Article CAS PubMed PubMed Central Google Scholar

Carpene, G. et al. Blood lactate concentration in COVID-19: a systematic literature review. Clin. Chem. Lab. Med. 60, 332–337 (2022).

Article CAS PubMed Google Scholar

Battaglini, D., Lopes-Pacheco, M., Castro-Faria-Neto, H. C., Pelosi, P. & Rocco, P. R. M. Laboratory biomarkers for diagnosis and prognosis in COVID-19. Front. Immunol. 13, 857573 (2022).

Article CAS PubMed PubMed Central Google Scholar

Liang, W. et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern. Med. 180, 1081–1089 (2020).

Article CAS PubMed Google Scholar

Zabczyk, M. et al. Elevated lactate levels in acute pulmonary embolism are associated with prothrombotic fibrin clot properties: contribution of NETs formation. J. Clin. Med. 9, 953 (2020).

Article CAS PubMed PubMed Central Google Scholar

Lee, S. et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 599, 283–289 (2021).

Article CAS PubMed Google Scholar

Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).

Article CAS PubMed PubMed Central Google Scholar

Kozlov, A. M., Lone, A., Betts, D. H. & Cumming, R. C. Lactate preconditioning promotes a HIF-1alpha-mediated metabolic shift from OXPHOS to glycolysis in normal human diploid fibroblasts. Sci. Rep. 10, 8388 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, W. et al. Lactate is a natural suppressor of RLR signaling by targeting MAVS. Cell 178, 176–189.e115 (2019).

Article CAS PubMed PubMed Central Google Scholar

Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).

Article CAS PubMed PubMed Central Google Scholar

Yamamoto, E. A. & Jorgensen, T. N. Relationships between vitamin D, gut microbiome, and systemic autoimmunity. Front. Immunol. 10, 3141 (2019).

Article CAS PubMed Google Scholar

Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136.e1128 (2016).

Article CAS PubMed PubMed Central Google Scholar

Zuo, T. et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159, 944 (2020).

Article CAS PubMed Google Scholar

Hazan, S. et al. Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. BMJ Open Gastroenterol. 9, e000871 (2022).

Article PubMed Google Scholar

Yeoh, Y. K. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 698–706 (2021).

Article CAS PubMed Google Scholar

Sykes, D. L. et al. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 199, 113–119 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lechner-Scott, J., Levy, M., Hawkes, C., Yeh, A. & Giovannoni, G. Long COVID or post COVID-19 syndrome. Mult. Scler. Relat. Disord. 55, 103268 (2021).

Article CAS PubMed PubMed Central Google Scholar

Ferreira-Junior, A. S. et al. Detection of intestinal dysbiosis in post-COVID-19 patients one to eight months after acute disease resolution. Int. J. Environ. Res. Public Health 19, 10189 (2022).

Article CAS PubMed PubMed Central Google Scholar

Liu, Q. et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71, 544–552 (2022).

Article CAS PubMed Google Scholar

Rishi, P. et al. Diet, Gut Microbiota and COVID-19. Indian J. Microbiol. 60, 420–429 (2020).

Article CAS PubMed PubMed Central Google Scholar

Calder, P. C. Nutrition, immunity and COVID-19. BMJ Nutr. Prev. Health 3, 74–92 (2020).

Article PubMed PubMed Central Google Scholar

Jabczyk, M., Nowak, J., Hudzik, B. & Zubelewicz-Szkodzinska, B. Diet, probiotics and their impact on the gut microbiota during the COVID-19 pandemic. Nutrients 13, 3172 (2021).

Article CAS PubMed PubMed Central Google Scholar

Alberca, G. G. F. & Alberca, R. W. Nutrition and the microbiota post-COVID-19. Saudi. J. Gastroenterol. 27, 111–112 (2021).

Article CAS PubMed PubMed Central Google Scholar

Pettigrew, M. M., Tanner, W. & Harris, A. D. The lung microbiome and pneumonia. J. Infect. Dis. 223, S241–S245 (2021).

Article CAS PubMed Google Scholar

Dumas, A., Bernard, L., Poquet, Y., Lugo-Villarino, G. & Neyrolles, O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol. 20, e12966 (2018).

Article PubMed Google Scholar

Ceban, F. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav. Immun. 101, 93–135 (2022).

Article CAS PubMed Google Scholar

Holdsworth, D. A. et al. Comprehensive clinical assessment identifies specific neurocognitive deficits in working-age patients with long-COVID. PLoS ONE 17, e0267392 (2022).

Article CAS PubMed PubMed Central Google Scholar

Woo, M. S. et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2, fcaa205 (2020).

Article PubMed PubMed Central Google Scholar

Raman, B., Bluemke, D. A., Luscher, T. F. & Neubauer, S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J. 43, 1157–1172 (2022).

Article CAS PubMed PubMed Central Google Scholar

Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 23, 194–202 (2022).

Article CAS PubMed PubMed Central Google Scholar

Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133–146 (2023).

Article CAS PubMed PubMed Central Google Scholar

Raveendran, A. V., Jayadevan, R. & Sashidharan, S. Long COVID: an overview. Diabetes Metab. Syndr. 15, 869–875 (2021).

Article CAS PubMed PubMed Central Google Scholar

Castanares-Zapatero, D. et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann. Med. 54, 1473–1487 (2022).

Article CAS PubMed PubMed Central Google Scholar

Paul, B. D., Lemle, M. D., Komaroff, A. L. & Snyder, S. H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl Acad. Sci. USA 118, e2024358118 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wong, T. L. & Weitzer, D. J. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Med. (Kaunas.) 57, 418 (2021).

Google Scholar

Castro-Marrero, J. et al. Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 13, 2658 (2021).

Article CAS PubMed PubMed Central Google Scholar

Weinstock, L. B. et al. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 112, 217–226 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wechsler, J. B., Butuci, M., Wong, A., Kamboj, A. P. & Youngblood, B. A. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy 77, 1288–1291 (2022).

Article CAS PubMed Google Scholar

Pinto, M. D. et al. Antihistamines for postacute sequelae of SARS-CoV-2 infection. J. Nurse Pract. 18, 335–338 (2022).

Article PubMed PubMed Central Google Scholar

Glynne, P., Tahmasebi, N., Gant, V. & Gupta, R. Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines. J. Investig. Med. 70, 61–67 (2022).

Article PubMed Google Scholar

Bardelcikova, A., Mirossay, A., Soltys, J. & Mojzis, J. Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy. Phytother. Res. 36, 2042–2060 (2022).

Article CAS PubMed PubMed Central Google Scholar

Wright, J., Astill, S. L. & Sivan, M. The relationship between physical activity and long COVID: a cross-sectional study. Int. J. Environ. Res. Public. Health 19, 5093 (2022).

Article CAS PubMed PubMed Central Google Scholar

Wang, C. et al. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell Infect. Microbiol. 12, 861703 (2022).

Article CAS PubMed PubMed Central Google Scholar

Comelli, A. et al. Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. Front. Med. 9, 834354 (2022).

Article Google Scholar

Law, M. R., Wald, N. J. & Rudnicka, A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. J. 326, 1423–1427 (2003).

Article CAS Google Scholar

Jiang, W., Hu, J. W., He, X. R., Jin, W. L. & He, X. Y. Statins: a repurposed drug to fight cancer. J. Exp. Clin. Cancer Res. 40, 241 (2021).

Article CAS PubMed PubMed Central Google Scholar

Fan, J. et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism 107, 154243 (2020).

Article CAS PubMed PubMed Central Google Scholar

Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res. 120, 229–243 (2017).

Article CAS PubMed PubMed Central Google Scholar

McAuley, D. F. et al. Simvastatin in the acute respiratory distress syndrome. N. Engl. J. Med. 371, 1695–1703 (2014).

Article PubMed Google Scholar

Truwit, J. D. et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N. Engl. J. Med. 370, 2191–2200 (2014).

Article PubMed Google Scholar

Parihar, S. P., Guler, R. & Brombacher, F. Statins: a viable candidate for host-directed therapy against infectious diseases. Nat. Rev. Immunol. 19, 104–117 (2019).

Article CAS PubMed Google Scholar

Feng, Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome_acute lung injury. Eur. Rev. Med. Pharmacol. Sci. 22, 3190–3198 (2018).

CAS PubMed Google Scholar

Zhang, X. J. et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Mateb 32, 176–187.e174 (2020).

Article CAS Google Scholar

Rodriguez-Nava, G. et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit. Care 24, 429 (2020).

Article PubMed PubMed Central Google Scholar

Yetmar, Z. A. et al. Prior statin use and risk of mortality and severe disease from coronavirus disease 2019: a systematic review and meta-analysis. Open Forum Infect. Dis. 8, ofab284 (2021).

Article PubMed PubMed Central Google Scholar

Hariyanto, T. I. & Kurniawan, A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Int. J. Diabetes Metab. Syndr. 14, 1613–1615 (2020).

Article Google Scholar

Tikoo, K. et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem. Pharm. 93, 343–351 (2015).

Article CAS PubMed Google Scholar

Kornhuber, J., Tripal, P., Gulbins, E. & Muehlbacher, M. Functional inhibitors of acid sphingomyelinase (FIASMAs). Handb. Exp. Pharm. 215, 169–186 (2013).

Article CAS Google Scholar

Zhemkov, V. et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains. Elife 10, e65192 (2021).

Article CAS PubMed PubMed Central Google Scholar

Vela, J. M. Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy? Front. Pharmacol. 11, 582310 (2020).

Article CAS PubMed PubMed Central Google Scholar

Ishima, T., Fujita, Y. & Hashimoto, K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur. J. Pharmacol. 727, 167–173 (2014).

Article CAS PubMed Google Scholar

Hoertel, N. et al. Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study. Clin. Pharmacol. Ther. 110, 1498–1511 (2021).

Article CAS PubMed Google Scholar

Darquennes, G., Le Corre, P., Le Moine, O. & Loas, G. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. Pharmaceuticals 14, 226 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lenze, E. J. et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA 324, 2292–2300 (2020).

Article CAS PubMed PubMed Central Google Scholar

Reis, G. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob. Health 10, E36–E45 (2022).

Article Google Scholar

Freites Nunez, D. D. et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 1393–1399 (2020).

Article PubMed Google Scholar

Rentsch, C. T. et al. Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States Veterans aged 54-75 years. Preprint at medRxiv https://doi.org/10.1101/2020.04.09.20059964 (2020).

de Bruin, N. et al. Ibuprofen, flurbiprofen, etoricoxib or paracetamol do not influence ACE2 expression and activity in vitro or in mice and do not exacerbate in-vitro SARS-CoV-2 infection. Int. J. Mol. Sci. 23, 1049 (2022).

Article PubMed PubMed Central Google Scholar

Chen, J. S. et al. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J. Virol. 95, e00014–e00021 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sodhi, M. & Etminan, M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest 158, 55–56 (2020).

Article CAS PubMed Google Scholar

Moore, N., Bosco-Levy, P., Thurin, N., Blin, P. & Droz-Perroteau, C. NSAIDs and COVID-19: a systematic review and meta-analysis. Drug Saf. 44, 929–938 (2021).

Article CAS PubMed PubMed Central Google Scholar

Schmidt, M. et al. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J. Thromb. Haemost. 9, 1326–1333 (2011).

Article CAS PubMed Google Scholar

Rabausch, K. et al. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ. Res. 96, e1–e6 (2005).

Article CAS PubMed Google Scholar

FitzGerald, G. A. Misguided drug advice for COVID-19. Science 367, 1434 (2020).

Article PubMed Google Scholar

Maeba, S. et al. Effect of montelukast on nuclear factor kB activation and proinflammatory molecules. Ann. Allergy Asthma Immunol. 94, 670–674 (2005).

Article CAS PubMed Google Scholar

Tahan, F., Jazrawi, E., Moodley, T., Rovati, G. E. & Adcock, I. M. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin. Exp. Allergy. 38, 805–811 (2008).

Article CAS PubMed Google Scholar

Camera, M., Canzano, P., Brambilla, M. & Rovati, G. E. Montelukast inhibits platelet activation induced by plasma from COVID-19 patients. Front. Pharmacol. 13, 784214 (2022).

Article CAS PubMed PubMed Central Google Scholar

Luedemann, M. et al. Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. Comput. Struct. Biotechnol. J. 20, 799–811 (2022).

Article CAS PubMed PubMed Central Google Scholar

Thoms, M. et al. Structural basis for translational shutdown and immune evasion by the Nsp1. Science 369, 1249 (2020).

Article CAS PubMed PubMed Central Google Scholar

Afsar, M. et al. Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2. Elife 11, e74877 (2022).

Article CAS PubMed PubMed Central Google Scholar

Khan, A. R. et al. Montelukast in hospitalized patients diagnosed with COVID-19. J. Asthma 59, 780–786 (2022).

Article CAS PubMed Google Scholar

Kerget, B., Kerget, F., Aydin, M. & Karasahin, O. Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19. J. Med. Virol. 94, 1950–1958 (2022).

Article CAS PubMed PubMed Central Google Scholar

Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101 (2014).

Article CAS PubMed PubMed Central Google Scholar

Serhan, C. N. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. Faseb. J. 31, 1273–1288 (2017).

Article CAS PubMed PubMed Central Google Scholar

Regidor, P. A., Santos, F. G., Rizo, J. M. & Egea, F. M. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. Med. Hypotheses 145, 110340 (2020).

Article CAS PubMed PubMed Central Google Scholar

Ramirez-Santana, M. et al. Inverse association between omega-3 index and severity of COVID-19: a case-control study. Int. J. Environ. Res. Public Health 19, 6445 (2022).

Article CAS PubMed PubMed Central Google Scholar

Doaei, S. et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. J. Transl. Med. 19, 128 (2021).

Article CAS PubMed PubMed Central Google Scholar

Weill, P., Plissonneau, C., Legrand, P., Rioux, V. & Thibault, R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? Biochimie 179, 275–280 (2020).

Article CAS PubMed PubMed Central Google Scholar

Mesri, E. A. & Lampidis, T. J. 2-Deoxy-d-glucose exploits increased glucose metabolism in cancer and viral-infected cells: relevance to its use in India against SARS-CoV-2. IUBMB Life 73, 1198–1204 (2021).

Article CAS PubMed PubMed Central Google Scholar

Sasaki, K. et al. Nanoparticle-mediated delivery of 2-deoxy-d-glucose induces antitumor immunity and cytotoxicity in liver tumors in mice. Cell Mol. Gastroenterol. Hepatol. 11, 739–762 (2021).

Article CAS PubMed Google Scholar

Rho, J. M., Shao, L. R. & Stafstrom, C. E. 2-Deoxyglucose and beta-hydroxybutyrate: metabolic agents for seizure control. Front. Cell Neurosci. 13, 172 (2019).

Article CAS PubMed PubMed Central Google Scholar

Bhatt, A. N. et al. Glycolytic inhibitor 2-deoxy-D-glucose attenuates SARS-CoV-2 multiplication in host cells. Life Sci. 295, 120411 (2021).

Article Google Scholar

Dwarakanath, B. S. & Jain, V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol. 5, 581–585 (2009).

Article CAS PubMed Google Scholar

Voss, M. et al. Rescue of 2-deoxyglucose side effects by ketogenic diet. Int. J. Mol. Sci. 19, 2462 (2018).

Article PubMed PubMed Central Google Scholar

Bhatt, A. N. et al. 2-Deoxy-D-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial. BMC Infect. Dis. 22, 669 (2022).

Article CAS PubMed PubMed Central Google Scholar

Bai, B. & Chen, H. Metformin: a novel weapon against inflammation. Front. Pharmacol. 12, 622262 (2021).

Article CAS PubMed PubMed Central Google Scholar

Yi, Y. et al. Metformin promotes AMP-activated protein kinase-independent suppression of delta Np63 alpha protein expression and inhibits cancer cell viability. J. Biol. Chem. 292, 5253–5261 (2017).

Article CAS PubMed PubMed Central Google Scholar

Yi, Y., Zhang, W., Yi, J. & Xiao, Z. X. Role of p53 family proteins in metformin anti-cancer activities. J. Cancer 10, 2434–2442 (2019).

Article CAS PubMed PubMed Central Google Scholar

Wang, C., Chen, B., Feng, Q., Nie, C. & Li, T. Clinical perspectives and concerns of metformin as an anti-aging drug. Aging Med. 3, 266–275 (2020).

Article Google Scholar

Khunti, K. et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 9, 293–303 (2021).

Article CAS PubMed PubMed Central Google Scholar

Lalau, J. D. et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 47, 101216 (2021).

Article CAS PubMed Google Scholar

Luo, P. et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg. 103, 69–72 (2020).

Article CAS PubMed PubMed Central Google Scholar

Chen, Y. et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43, 1399–1407 (2020).

Article CAS PubMed Google Scholar

Afshari, K. et al. Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: introduction of an alternative therapy. Spinal Cord. 56, 1032–1041 (2018).

Article PubMed Google Scholar

Jadhav, S. et al. Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 48, 956–963 (2006).

Article CAS PubMed Google Scholar

Ursini, F. et al. Metformin and autoimmunity: a “new deal” of an old drug. Front. Immunol. 9, 1236 (2018).

Article PubMed PubMed Central Google Scholar

Rangarajan, S. et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 24, 1121–1127 (2018).

Article CAS PubMed PubMed Central Google Scholar

Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017).

Article CAS PubMed PubMed Central Google Scholar

Choi, K. S., Aizaki, H. & Lai, M. M. Murine coronavirus requires lipid rafts for virus entry and cell-cell fusion but not for virus release. J. Virol. 79, 9862–9871 (2005).

Article CAS PubMed PubMed Central Google Scholar

Guo, H. et al. The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain. PLoS ONE 12, e0170123 (2017).

Article PubMed PubMed Central Google Scholar

Wei, X., She, G., Wu, T., Xue, C. & Cao, Y. PEDV enters cells through clathrin-, caveolae-, and lipid raft-mediated endocytosis and traffics via the endo-/lysosome pathway. Vet. Res. 51, 10 (2020).

Article CAS PubMed PubMed Central Google Scholar

Sviridov, D., Miller, Y. I., Ballout, R. A., Remaley, A. T. & Bukrinsky, M. Targeting lipid rafts-a potential therapy for COVID-19. Front. Immunol. 11, 574508 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, R., Wang, Q. & Yang, J. Potential of sphingosine-1-phosphate in preventing SARS-CoV-2 infection by stabilizing and protecting endothelial cells. Medicine 101, e29164 (2022).

Article CAS PubMed PubMed Central Google Scholar

Maceyka, M. & Spiegel, S. Sphingolipid metabolites in inflammatory disease. Nature 510, 58–67 (2014).

Article CAS PubMed PubMed Central Google Scholar

Shulla, A. & Gallagher, T. Role of spike protein endodomains in regulating coronavirus entry. J. Biol. Chem. 284, 32725–32734 (2009).

Article CAS PubMed PubMed Central Google Scholar

Zhang, J. T. et al. Positive-strand RNA viruses stimulate host phosphatidylcholine synthesis at viral replication sites. Proc. Natl Acad. Sci. USA 113, E1604–E1073 (2016).

Google Scholar

Lee, J. Y. et al. Spatiotemporal coupling of the hepatitis C virus replication cycle by creating a lipid droplet- proximal membranous replication compartment. Cell Rep. 27, 3602–3617.e3605 (2019).

Article CAS PubMed Google Scholar

Bang, B. R. et al. Regulation of hepatitis C virus infection by cellular retinoic acid binding proteins through the modulation of lipid droplet abundance. J. Virol. 93, e02302–e02318 (2019).

Article CAS PubMed PubMed Central Google Scholar

Criglar, J. M., Estes, M. K. & Crawford, S. E. Rotavirus-induced lipid droplet biogenesis is critical for virus replication. Front. Physiol. 13, 836870 (2022).

Article PubMed PubMed Central Google Scholar

Martins, A. S., Martins, I. C. & Santos, N. C. Methods for lipid droplet biophysical characterization in flaviviridae infections. Front. Microbiol. 9, 1951 (2018).

Article PubMed PubMed Central Google Scholar

Zandi, M. et al. Interplay between cellular metabolism and DNA viruses. J. Med. Virol. 94, 5163–5173 (2022).

Article CAS PubMed Google Scholar

Martinez-Ramirez, I. et al. Regulation of cellular metabolism by high-risk human papillomaviruses. Int. J. Mol. Sci. 19, 1839 (2018).

Article PubMed PubMed Central Google Scholar

Park, G. J. et al. The mechanism of RNA capping by SARS-CoV-2. Nature 609, 793–800 (2022).

CAS PubMed PubMed Central Google Scholar

Walker, A. P. et al. The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme. Nucleic Acids Res. 49, 13019–13030 (2021).

Article CAS PubMed PubMed Central Google Scholar

Bracquemond, D. & Muriaux, D. Betacoronavirus assembly: clues and perspectives for elucidating SARS-CoV-2 particle formation and egress. mBio 12, e0237121 (2021).

Article PubMed Google Scholar

Wang, X., Melino, G. & Shi, Y. Actively or passively deacidified lysosomes push beta-coronavirus egress. Cell Death Dis. 12, 235 (2021).

Article CAS PubMed PubMed Central Google Scholar

Henne, M. And three’s a party: lysosomes, lipid droplets, and the ER in lipid trafficking and cell homeostasis. Curr. Opin. Cell Biol. 59, 40–49 (2019).

Article CAS PubMed Google Scholar

Jaishy, B. & Abel, E. D. Lipids, lysosomes, and autophagy. J. Lipid Res. 57, 1619–1635 (2016).

Article CAS PubMed PubMed Central Google Scholar

Xu, L., Yang, C. S., Liu, Y. & Zhang, X. Effective regulation of gut microbiota with probiotics and prebiotics may prevent or alleviate COVID-19 through the gut-lung axis. Front. Pharmacol. 13, 895193 (2022).

Article CAS PubMed PubMed Central Google Scholar

de Oliveira, G. L. V., Oliveira, C. N. S., Pinzan, C. F., de Salis, L. V. V. & Cardoso, C. R. B. Microbiota modulation of the gut-lung axis in COVID-19. Front. Immunol. 12, 635471 (2021).

Article PubMed PubMed Central Google Scholar

Zhang, M. et al. COVID-19: gastrointestinal symptoms from the view of gut-lung axis. Eur. J. Gastroenterol. Hepatol. 33, 610–612 (2021).

Article CAS PubMed Google Scholar

Download references

The work was supported by grants from The Science Technology and Innovation Committee of Shenzhen Municipality [JCYJ20180507181627057 to M.-L.H., JGSS20200225152648408, 20220606141401003 to Y.H.]; RGC General Research Fund of Hong Kong Special Administrative Region [11104020] and Strategic funds from City University of Hong Kong to M.-L.H.

Department of Biomedical Sciences, City University of Hong Kong, HKSAR, Hong Kong, China

Peiran Chen, Mandi Wu & Ming-Liang He

Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, Guangdong, China

Yaqing He

Cell Signaling and Proteomic Center, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China

Binghua Jiang

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

All authors have read and approved the final version of the submitted manuscript. M.-L.H. and P.C. conceptualized and designed the article. P.C. did literature research, wrote the manuscript, and drafted figures. M.-L.H., Y.H., B.J., and M.W. revised the manuscript.

Correspondence to Ming-Liang He.

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Chen, P., Wu, M., He, Y. et al. Metabolic alterations upon SARS-CoV-2 infection and potential therapeutic targets against coronavirus infection. Sig Transduct Target Ther 8, 237 (2023). https://doi.org/10.1038/s41392-023-01510-8

Download citation

Received: 25 November 2022

Revised: 18 April 2023

Accepted: 19 May 2023

Published: 07 June 2023

DOI: https://doi.org/10.1038/s41392-023-01510-8

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative